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INTRODUCTION

Breast cancer was the leading cause of death by cancers among women in the United Stales
until 1987. Only then did lung cancers supercede it in fatalities (Vital Statistics of the United

Slates, 1996). Whereas lung cancers have several recognized ’’causes", the avoidance of which

minimizes one’s risks dramatically, breast cancer etiology is not as clear.
Diet reportedly has some bearing on the risk factors for breast cancer, as is noted for other

diseases. Nutritional studies indicate that a well-balanced diet, with emphasis on fruits and
xegetablcs, promotes longevity. The dietary indoles in cruciferous vegetables were found to
decrease cancer incidence in animal models, apparently through the induction of cytochrome P450

enzymes (Michnovicz, 1990). Other groups claim special "preventive" properties exist in diets

high in fish oils (ligo, 1997; Rose, 1997), in fiber (De Stefani, 1997; Skankar, 1991), green tea
(Weisburger, 1997; Imai, 1997), soybean (Stoll, 1997; Yan, 1997), and garlic (Riggs, 1997;

Pinto, 1997). Antioxidant \ ilamins and mineral supplements were also heralded as "therapy
(Block, 1991; Blot, 1993; Byers, 1992). Several of these food groups do have beneficial effects,

reportedly lowering the risks for cancer. No given nutrient, however, has been proven either to
prevent or to cure breast cancer (Am. Cancer Society Advisory Committee on Diet, Nutrition, and
Cancer Prevention, 1996).

Behavior also is not the answer to a cancer-free life. Exercise is encouraged and indeed

does improve one's overall health and quality of living (Shephard, 1993). Avoidance of alcohol,

drugs, and tobacco is likewise accepted as advantageous, but again, is no guarantee (Marshall,
1996; Cheng, 1996). Cancers have been linked to radiation exposure (Ponnaiya, 1997), high

stress, and even to low level fields of magnetic resonance, pulsed (Ubeda, 1994) or produced trom
ox erhead high voltage transmission electric lines (Theriault, 1997; Feychling, 1995), but in the

populations not exposed, cancers still exist.
Epidemiological studies have uncovered familial links implicating genetic anomalies to
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breast cancer. Through the studies of Ashkenazi Jewish women, researchers discovered that

abnormalities on chromosome 17 predisposed women to breast cancer (Hall, 1990). Further work
identified the gene, dubbed BRCA 1, with "hot spots" of dclctions/inscrtions at locus 17q21 (Miki,
1994). A second "breast cancer gene", BRCA2 al 13q 12-13 (Wooster, 1995), when carrying
germ-line mutations, increases one's risk of developing the disease to 70% by age 70 in women

and increases men’s lifetime risk 200-fold (Couch, 1996). Mutations affecting both alleles in
either BRCA 1 or BRCA2 account for nearly 50% of early-onset breast cancers in the Ashkenazi
Jews (Bowcock, 1997).

Not only has genetic damage been linked to cancer through documented hereditary
predispositions such as these, but also by the assignment of carcinogenicity based on mutagenic
potential of substances (Ames, 1979) and from the observation of mutated chromosomes in cancer
cells (Rowley, 1984). Typical mutations include translocations or inversions within chromosomes

(Klein, 1983; Nowell, 1960; Nowell, 1985), delelions/insertions (Nusse, 1986), and/or abnormal

amplifications of large domains (Lillie, 1983; Schwab, 1985). The role of retroviruses in initiating
tumorigenesis and the subsequent recognition of certain cellular genes' involvement therein

expanded our awareness of the genetic component of cancer (Bishop, 1983; Varrnus, 1982). That
faulty repair mechanisms for DNA were linked to increased cancer risk was one more indication of

genetic involvement in cancer (Bishop, 1987).
The relationship between loss of self-repair in damaged DNA and cancer susceptibility is

the driving force in the search for tumor-suppressor genes (TSGs). When truncation of specific
alleles correlates to high incidence of cancers, as in 87% of BRCA 1 and 100% of BRCA2

mutations (Couch, 1996), loss of a tumor-suppressor gene is suspected. That different regions of
chromosomes house tumor-suppressor genes is commonly investigated using probes of highly
polymorphic (C-A)n microsatellite repeals. Table 1 lists loci for some putative TSGs identified by

this method as well as by other cytogenetic evaluations. Eventual medicinal application of
transfection in which disabled genes are replaced with viable alleles is a strong contender for a
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working cure for cancer (Slovak, 1996).
The complexity of factors involved in cancer, however, suggests that reinstatement of any

given tumor-suppressor gene will not be adequate for curtailment of pathology of the breast. The
most frequently mutated gene occurring in sporadic breast cancer is p53, a well recognized tumor
suppressor gene. One study correlated p53 gene mutations in breast tumors with poor prognosis
and decreased survival limes (Gudas, 1995). In another study of 192 primary breast cancers,
however, there was no significant difference in survival rates for patients harboring mutated versus

wild-type p53 alleles (Caleffi, 1994). The molecular interaction of growth factors, hormones, and

proteins such as p53 involves loo many as-of-yet undefined parameters regulating cell growth,

differentiation, and apoptosis to be corrected with any single treatment.
TABLE 1

Relevance to Breast Cancer

Loci for P utative TSGs

w/i 16cM of lq21 -3 1
lp32-pler
lp36
lq41-44
3pl 1-14,14-23,24-26
6ql3-21
6q23-24

c-myc associated function
Loss of Helerogosity (LOH)
Preferential association with clonal
evolution of cancer

6q27
7q31.1-q31.2
1 lql3

TP53 mutations associated with LOH
LOH pinpointing lost MEN-1 TSG
(multiple endocrine tumor)
TH-HBB region; Harvey-Ras
PR gene; LOH

1 lpl5
Hp22-23
1 lq23.3
13ql2-13
16q22-24

BRCA2
BBC1 (breast basic conserved-1 gene);
DPEP1 (dipeptidase-1 gene); E- and
M-cadherins: metastasis association
TP53
BRCA1

17pl3.1
17q21
17q25
17
20ql3

NME-1 metastasis inhibitor protein (nm23)

(Slovak, 1996)
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Mechanisms governing growth must be elucidated and ultimately manipulated in order to
stem the growth of cancers. Genes directly involved in early responses to mitogens, the

prolooncogenes, arc logical targets of investigation. These were initially discovered during the

study of the life cycles of rctroviruses. Protooncogenes are described as cellular counterparts to
those retroviral oncogenes implicated in turnongenesis ("proto" meaning "earliest form of" and

"onco" meaning "tumor"). Il is believed that viruses acquired these growth-governing genes via

transduction with mutations occurring enroute that rendered them oncogenic. Of the 20 retroviral
oncogenes providing models for neoplasms, 9 have recognized cellular versions (abl, erbB, ets,

mos, myb, myc, H-ras, K-ras, and sis; prefix "c-" for cellular and "v-" for viral). Mutations
resulting in overexpression of protooncogenes can transform established cell lines but usually not
primary explants of normal cells. Exceptions to this are c-myc and c-H-ras which can transform
even normal primary explants and c-src which cannot elicit neoplastic phenotypes even in cell line
cultures (Bishop, 1987).

Amplification of prolooncogenes is implicated in the progression of neoplasms rather than

in their initiation (Winter, 1986). Of the several prolooncogenes involved in carcinogenesis, c-myc
at locus 8q24 is very illustrious. In Burkitt's lymphoma, the chromosome carrying c-myc has
experienced a translocation mutation (Klein, 1983; Hann, 1988). In other diseases, including

small cell lung cancer (SCLC) and carcinoma of the breast (Nau, 1985; Ou, 1996), amplifications

in myc genes have been identified in over 20% of human tumors studied (Bishop, 1987). In one
slud\ of 185 breast cancers, the most frequent clonal gain was on chromosome 8 in which genes

for c-myc and the FGF receptor gene FGFR are affected (Slovak, 1996). Overexpression of the

related L-myc, initially cloned from SCLC, has been shown to induce oncogenic transformation
upon its own dysregulation (Bossone, 1985). Cases of mvc mutations being involved in
pathogenesis of cancer are well documented in the literature, illustrating once again the complexity

of one factor affecting cancer initiation and progression.
Researchers increasingly probe for clues as to what causes cancer. The data suggest that
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lifestyle and environmental factors arc implicated in up to 80% of cancers, although risk factorassociated cases of breast cancer were reportedly only 25-29% (Seidman, 1982) or at most 55%

(Bruzzi, 1985). The risk factors recognized currently are age, family history, reproductive factors.
and a previous history of benign breast disease. A summary' of these factors and their relative risks
are outlined in Table 2. The contribution of hormones to these risks is suggested by the data, and

indeed, has been verified for estrogen and progesterone (Bilimoria, 1995).
TABLE2

Summary of Breast Cancer Risk Factors
Risk Factors for Breast Cancer

Relative Contribution to Disease State

Family History
First-degree relative with breast cancer
Premenopausal
Premenopausal and bilateral
Postmenopausal
Postmenopausal and bilateral
Menstrual History
Age at menarche less than 12
menopause greater than 55
Pregnancy
1st live birth from ages 25-29
after age 30
after age 35
Nulli parous
Benign Breast Diseases
Proliferative disease
Proliferative disease with atypical hyperplasia
Lobular carcinoma in situ

1.2-3.0
3.1
8.5-9.0
1.5
4.0-5.4
1.3
1.5-2.0
1.5
1.9
2.0-3.0
3.0

1.9
4.4
6.9-12.0

(Bilimoria, 1995)

Estrogen and progesterone are members of the steroid family of hormones which operate
through nuclear receptors. The nuclear receptor superfamily includes receptors not only for the

classical sterioids, estrogen, progesterone, glucocorticoids, mineralocorticoids, and androgens, but

also for retinoic acid, thyroid hormone, vitamin D3. and the so-called orphan receptors whose
ligands have not yet been identified. Steroid hormones originate from cholesterol. The cholesterol

is transported in the blood by lipoproteins and enters cells where monooxygenases hydroxylate it.
The sequential action of several enzvmes within cells further metabolize the choleslerol-metabolite
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to the specif ic hormone which is then secreted once again into the bloodstream (Clark, 1992).
Hormones, at concentrations from the picomolar to above the nanomolar range, circulate in

the plasma bound to serum proteins. Among the many scrum proteins are testosterone-binding
globulin (TeBG) w hich binds estrogen and androgens with a Kj of 10-10 M (Soloff, 1971) to
10-9 M (Griffin, 1992) and corticosteroid-binding globulin (CBG) which binds glucocorticoids and
progesterone with a Kd of 10-9M (Griffin, 1992). The equilibrium dissociation constant, K^, is a
measure of the tightness with which tw o substances bind, the lower the

value, the tighter the

binding. A Kj of 10-9 M means that at nanomolar concentrations the hormone binds 50% of the

globulin proteins. Being hydrophobic in nature, free hormone can diffuse across the plasma and
nuclear membranes of all cells. Il remains only in those cells which house receptors specific for

the given hormone, these receptors having an affinity for the hormone 10-fold greater than that of
serum proteins (Kj = 10-tOM).
Steroid receptors classically meet certain criteria to receive "receptor" status. Firstly, there

must be a limited number of receptors per unit mass of tissue with a finite binding capacity; hence
binding is saturable. Because hormones circulate at such low concentrations, receptors must
exhibit high affinity for their respective ligands. High affinities for specific hormones enable

receptors to discriminate among the choices of potential ligands. Although absolute
stereospecificity is not achieved, receptors do display steroid specificity. Location of the receptors
limits biological responses to those organs/tissues/cells which are appropriate targets. For the

binding of receptors to be meaningful, there must be, of course, this biological response (Clark,
1992).

Members of the nuclear receptor superfamily have three regions of consensus homology.
designated as Cl, C2, and C3, shown below. Cl is the most highly conserved, housing the

cysteine-rich DNA binding domain. The functional significance of the homologies in C2 and C3
have yet to be determined (Clark, 1992).
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Illustration 1: The Steroid Receptor Supergene Family Homology of Consensus Domains

MR

N- ,
I

PR
AR

r

GR
ER
RAR
T3B
VDR

r

Cl

i
i
I
I

ci
Cl ~
Cl

r ci

C2
C2 C3
I
C2
C3 I
C2 T3 I

C2 C3
I
Cl C? C3
Cl ~~C7
C3 I
C2
O
CT I

amino acids
984
934
918
777
595
462
456
427

(Clark, 1992)

Illustration 2: Functional Domains of the Steroid Receptors
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Domain A/B - transactivation function; transcription activation function-1 (TAF-1)
C - DNA binding
D - hinge region
E - ligand binding; dimerization; TAF-2
F - unknown function
The liganded receptors act primarily by modulating transcription via interaction with
discrete regions of DNA termed Steroid (or Hormone) Response Elements (SRE or HRE). These

SREs arc enhancer elements, commonly found in the 5' upstream region of genes, but are

effective regardless of position or orientation. In general, SREs are imperfect hexanucleotide
palindromes separated by spacers of differing lengths. The palindromic nature of SREs suggests
that receptors interact with these elements as functional dimers. The transcriptional response to

steroids is controlled by much more than mere binding of the hormone-receptor complex to its
SRE. In fact, the full role of hormones in gene transcription has yet to be resolved (Carr, 1992).
Much controversy exists concerning absolute requirement for ligand involvement, hormone-
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receptor interaction with transcriptional machinery, receptor function, and mechanism(s) of gene
activation. For years the exact mechanism by which the hormone bound to its receptor arrived in
the nucleus was unsettled. At one point it was thought that the unoccupied receptors were

exclusively cytoplasmic. It was thought that chaperone proteins such as the heat shock proteins

hsp90 and hsp70 were bound to the receptors, thereby effecting a conformation of the receptor
conducive to ligand binding. Upon receptor binding of hormone, the heat shock proteins
dissociated, the liganded receptor underwent "activation" or " transformation", and the complex

was transported to the nucleus by unknown mechanisms. This theory7, commonly called The TwoStep Mechanism, had several variations, but the consensus was that (1) the hormone induced
conversion of the native cytoplasmic receptor protein to a biochemically active form that then (2)

reacted with target genes (Hansen, 1988). Experimental evidence for this was the observance of

liganded receptors' presence in the nuclear fraction versus the cytoplasmic localization of
unliganded receptors in cells following homogenization and differential centrifugation (Gorski,

1968; Jensen, 1968). Re-examination of the cellular location of unoccupied steroid receptors
began with the demonstration of high aporeceptor yields in the nuclear fraction following

ultracentrifugation of highly concentrated homogenates (Sheridan, 1979; Welshons, 1984).
This re-evaluation continued with the development of new investigative techniques.

Production of monoclonal antibodies for steroid receptors and the advent of immunocytochemistry7
allowed the issue of cellular localization to be reexamined. Using non-disruptive in situ

hybridization, researchers could demonstrate that both the free and occupied receptors were
localized to the nucleus for all steroids but the glucocorticoids (Gorski, 1976; King, 1984). The

glucocorticoid receptor (GR) apparently maintains an equilibrium between the cytoplasm and
nucleus (Griffin, 1992).

A limitation of immunocytochemical identification of receptor localization has been
illustrated, however, with the discovery of membrane-bound estrogen receptors operating through
nongenomic estrogen-dependent pathways in pituitary tumor cells (Pappas, 1995). Epitopes on
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the receptors against which the antibodies were generated may not always be available on the
various forms of receptors possibly existing in the cell. Visualization of the location of antibodies

with conventional fluorescence microscopy also was hampered by the spatial noise and flare

intrinsic to the device (Pappas, 1995). Evidence that steroids interact with other proteins in the
membrane has been reported for estrogen (Smith, 1989), glucocorticoids (Gametchu, 1993), and

progestin metabolites (Majewska, 1992). Whether or not these interactions arc mediated by

conventional or modified steroid receptors has not been unequivocally determined.
When steroid hormones act to alter transcription rates of targeted genes, what mechanisms
arc employed? Apparently, nuclear localization of receptors is not hormone-dependent. It was

postulated that hormone binding caused conformational changes in receptors necessary for the
required dimerization of receptors preresquisite to their binding to the HREs. Furthermore, it was

supposed that liganded receptors have increased affinity for HREs. These issues have been
investigated extensively for the estrogen-estrogen receptor complex.
In one study it was shown that the unliganded, or aporeceptor, for estrogen existed as a

phosphoprolein. After hormone treatment, the receptor was hyperphosphorylated and became

biologically active. Hyperphosphorylation of the estrogen receptor (ER) was correlated with
increased nuclear retention and DNA binding (Denton, 1992). Another study demonstrated that the

aporeceptor bound the estrogen response element (ERE) weakly, and it was only upon addition of
estradiol that the ER dimerized and tightly bound the ERE (Kumar, 1988). Nonliganded ER was

held loosely in the nucleus, easily extracted upon homogenization in hypotonic buffers (Welshons,

1984). With the addition of hormone, however, the ER tightly bound the chromatin, requiring a

salt concentration of 0.4M and higher to extract (Gorski, 1976). Using recombinant techniques
with the human estrogen receptor (hER), Notides and co-workers demonstrated that the hER
exhibits positive cooperativity for estradiol binding, and at physiological ER concentrations the
estrogen receptor exists as a dimer (Obourn, 1993).

These findings are contrasted to those of Katzenellenbogen and co-workers in which
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similiar levels of ER and RNA polymerase II were associated with chromatin regardless of pre
exposure to ligand (Wrenn, 1990). The unliganded ER altered gene transcription by binding
promoter regions. This ligand-independent transactivation was possibly due to the transactivation

function-1 (TAF-1) of the ER. Although ligands were not necessary for ER-ERE interaction, they
were thought to aid in stabilizing the ER within the cells in lieu of heat shock proteins (hsp). Their
data suggested the interaction of ER with heat shock proteins was an in vitro artifact as more than
half the ERs were not bound by inhibitory proteins (e.g. hsp90) in whole cells. Ligands may also

stabilize ER dimerization, thus effecting increased DNA binding (Reese, 1992).

Other workers likewise report ER's ability to bind ERE oligonucleotides in the absence of

ligand or other proteins (Curtis, 1992; Furlow, 1993; Klein-Hitpass, 1989). Dimerization of the
estrogen receptor was not directly induced by estradiol (Furlow, 1993), nor was ER dimerization

necessary for interaction of the receptor with ERE oligonucleotides (Medici, 1991). A single

mutation destroying the dyad symmetry of the 13-bascpair consensus ERE (GGTCAnnnTGACC)

did not prevent ER interaction, although this interaction was limited to monomers (Medici, 1991).
This supports a physiological role for GGTCA half-element pairs in estrogen-induced activation of

the chicken ovalbumin gene (Tora, 1988).

Evidence from Gorski and co-workers supports the model that hormone is not required for
ER-ERE interaction. Furthermore, in contrast to previous reports, their data suggest that
homodimer formation is not only unnecessary, but also does not occur as the active ER form.
High affinity binding of the ER to a consensus vitellogenin estrogen response element (vit ERE)

exhibits a stoichiometry of 1 mole ER to 1 mole vit ERE, suggesting the active form is a monomer.

Estrogen is seen as an inducer of protein-protein, but not protcin-DNA, interactions (Furlow,
1993).

Examined al a thermodynamic level, the interaction of the estrogen receptor with an
estrogen-responsive DNA sequence was found to display similiar dissociation rate constants (k_i)

and equilibrium dissociation constants (Kj) regardless of whether ER was ligand-free or bound by

10

agonist or antagonist. Curtis and Korach concur with Furlow cl al. in that the ligand-binding
domain of the ER does not exert a regulatory effect al the level of sequence-specific DNA binding
(Curtis, 1992). Even the assumption that an estrogen response reflects relative ERE occupancy of
the activated ER may not be fully correct. Webb and co-workers found that EREs were occupied

to a very small extent (less than 10%) under normal conditions. The capacity of the cell then
greatly exceeds the ER concentration normally found in estrogen-responsive cells, i.e. 1-8 x 104
ER/cell. This raises the possibility that estrogen induction is controlled by other parameters, such
as the further binding of the receptor to some limiting factor required for full receptor activation.
The ER-ERE complexes may be inactive in vivo in the absence of such a factor (Webb, 1992).

An alternate possibility is that the ERE is not always involved in ER-mediated transcription
as was noted for the ovalbumin gene in which transcriptional activation occurred indirectly via

interaction of ER w ith the fos-jun complex (Gaub, 1990). Transcription of the human
glycoprotein hormone a-subunit gene is negatively regulated by estrogen in the absence of high

affinity binding siles/EREs for the ER. Sequences from the 5' flanking region of this gene when

transfected into heterologous cell lines likewise fail to bind ER but confer estrogen responsiveness

in the form of transcriptional suppression (Keri, 1991). These incidences of ERE-independent
estrogen regulation of transcription, how ever, seem to be more the exception than the general rule.
Il is well documented that ER-ERE binding serves to enhance gene activation. That several other

factors act in conjunction with this continues to be investigated.
The intermolecular engagement of ERs by other proteins has been observed to occur upon

activation of the receptor. Formation of these large complexes was found to be ligand-dependent.
inhibited by molybdate, and occurred even in the presence of RNase, DNase, and 0.4M KC1.

Proteolysis destroyed the complexes which had defined stoichiometry for their large, fixed
molecular size. Clearly these complexes involved the receptor with other proteins, but the identity
of these proteins had not yet been determined (Nelson, 1989).
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Work to identify and characterize those accessory’ receptor-associated proteins involved in

ER-DNA interactions employed immuno-, steroid-, and site-specific DNA-affinity chromatography
techniques. Proteins of 70 and 55 kilodaltons (kDa) were in all three column eluates. Proteins of
45- and 48-kDA w ere eluted in ER-specific affinity columns. The 70-kDa protein was identified as

hsp70 and the 55-kDa protein as a member of the protein disulfide isomerase (PDI) family, but the
identity of both the 45- and 48-kDa species was not resolved (Landell, 1994). Follow-up work by

Landell and co-workers demostrated that the four protein combination altered kinetics of ER-DNA
interaction, improving ER's ability to bind vitERE. These ER-associated proteins also induced

higher order ER-DNA complexes which significantly distorted DNA conformation (Landell,
1997).
Whether or not these proteins are absolutely essential for high affinity ERE binding is still

unresolved. One report claims hsp70 is required for maximal ERE binding when using highly

purified recombinant human ER (Greene, 1994). This finding has been contested by other
investigators. Although hsp70 was found associated with partially purified calf uterine ER, it

apparently was not responsible for increased ERE binding affinity, ligand retention, or total
amount of ER-ERE complexes formed. Furthermore, hsp70 did not affect the ER ligand binding
domain conformation once the estrogen receptor was activated and occupied by ligand (Klinge,
1997).
Another manner in which estrogen and/or its receptor regulates transcription may be in

facilitating the disruption of chromatin structure in the vicinity of the promoter to allow
transcriptional machinery access to deoxyribonucleotides. It has been shown that chromatin
templates around which nucleosomes are assembled are refractory to transcription (Schlissel, 1984;
Knezetic, 1986). Alleviation of the suppressive nature of nucleosomes on regulatory regions such
as promoters can occur upon addition of transcription factors before or during nucleosome

assembly (Workman, 1988). Disruption of chromatin structure over the promoter was reported to
be rapidly induced by hormone. DNase I-hypersensitivity, a measure of chromatin disruption,
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was not merely a consequence of receptor binding of DNA, but was greatly enhanced by the
presence of transactsvation factors. In fact, unless there were multiple steroid receptor dimers
binding adjacent SREs, no nucleosome displacement was observed (Pham, 1991).

The involvement of transcription factors in steroid induction of transcription should not be

minimized. Accessibility of these factors to the promoter greatly influences the observed results in
studies investigating regulation by chromatin. Differences between conclusions from in vitro and

in vivo experiments may well be due to the level at which reconstitution is achieved with respect to
auxiliary factors. The nuclear receptor co-activator (NCoA) gene family includes SRC-l/NCoA-1,
TIF-2/GRIP-1, CBP, pl60, and p/CIP which complexes with a significant portion of CBP in the
cell. Both p/CIP and NCoA-1 are required for proper functioning of the nuclear receptors for

retinoic acid, estrogen, progesterone, and the thyroid hormone (Torchia, 1997).
High levels of histone acetylation of associated DNA disrupt chromatin structure, making it

more susceptible to DNase I digestion (Vidali, 1978; Nelson, 1978). Sodium butyrate, an
inhibitor of histone deacetylase enzymes (Boffa, 1978; Sealy, 1978) causes extensive

hypcracelx lation of histones (Riggs, 1977) but was not found to affect overall rates of in vitro

transcription in isolated nuclei (Mathis, 1978; Moore, 1978), although this says nothing about the

comparative transcription rates of individual genes. The dosage of butyrate commonly used (5lOmM) max have affected observed results. Bartsch et al. demonstrated that butyrate

concentrations in excess of 4m M had inhibitory effects on basal and hormonally induced gene
transcription, whereas maximal stimulation occurred at 0.5-lmM (Bartsch, 1996). Later work

using the steroid retinoic acid (RA) provided evidence for hormone-induced alterations ot

chromatin structure that enabled accessibility within the promoter and was correlated with
transcriptional activation. The chromatin structure in and around the promoter underwent dynamic,

reversible changes without globally affecting nucleosomal organization (Bhattacharyya, 1997).
Other work has indicated an involvement of liganded ER in facilitating the opening of chromatin to

transcriptional machinery’ in the presence of the steroid receptor coactivator-1 (SRC-1). SRC-1 is
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believed to act in coordinating nuclear receptors' amino- and carboxyl-terminal transcripton
activation functions (TAF-1 and -2, respectively) for full activation of the receptor (McInerney,

1996). Identification of the steroid receptor coactivator-1 as a histone acetyltransferse (Spencer,

1997) further substantiates steroid involvement in gene activation at multiple levels.
Although controversy continues to exist as to the exact mechanisms by which hormones act

in regulating gene expression, it is undisputed that estrogen and progesterone affect the growth and
development of mammary tissues. In fetal life proliferating epithelial cells form approximately two

dozen short cords which become mammary ducts connected to the nipple. Alveolar structures
derive from the blind end of these ducts later in gestation. With the removal of placental estrogen
and progesterone, however, growth of the breast halts. Mammary development resumes shortly
before onset of menarche due to the increased secretion of ovarian estrogen. The ducts lengthen

and branch, and their terminal ends bud. Estrogen itself is not sufficient for induction of ductal

growth, but acts in concert with anterior pituitary hormones. Only in the presence of growth
hormone and prolactin does estrogen promote ductal development. Lobuloaveolar develpment is
controlled by progesterone and prolactin, although concomitant or preceeding estrogenic

stimulation is also required for full progestin activation (Frantz, 1992). The interplay between
these two steroid hormones can be antagonistic or stimulatory, depending on the particular cellular
environment (Gronemeyer, 1991; Kraus, 1995). This cross-talk between estrogen and

progesterone has added to the controversy surrounding their respective roles as mitogens in

mam man' cells.
The progesterone receptor has multiple isoforms, PR-A, PR-B, and, putatively, PR-C

(Wei, 1990), all arising from the same gene, locus 11 q 13 (Law, 1988), but differing in size due to

variations in transcription start sites. Data from the labs of Gronemeyer, Chambon, and Horwitz
suggest PR isoforms A and B are translated from different mRNAs (Kastner, 1990). This is

supported by the identification of multiple species of PR mRNA in normal human endometrium
and the breast cancer cell lines T47D and MCF-7 ranging from 2.8 kb to 11.4 kb (Read, 1988).
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Whereas PR-B originates from the first AUG codon, PR-A's start codon is located downstream,

but in-frame, at AUG 165. PR-C utilizes a methionine at codon 595 in exon 2 as its start codon.

The N-terminally truncated PR-C lacks the first DNA-binding zinc finger of PR but contains the
second zinc finger, the hinge region, and the hormone-binding domain (Wei, 1990). Additional
progesterone receptor mRNAs not encoding B- or A-receptors have also been isolated which could

be translated into PR-C. In vitro translated PR-C was found to act functionally in the presence of
PR-A and -B and may provide another means of modulating transcriptional activity of the
progesterone receptor (Wei, 1996).
Investigators have examined variations in estrogen and progesterone receptor content as a

function of age, menstrual, and menopausal status in breast cancer patients. Surprisingly,

fluctuations in steroid receptor content seen throughout age and menstrual cycling were not
correlated with blood levels of the steroid hormones in normal subjects. Within the carcinoma

groups, however, associations were observed betw een ER and PR content and blood steroid
hormone levels in the luteal phase of the menstrual cycle and within postmenopausal women
above 59 years of age. A decrease in ER in mid-cycle versus penmenstrual cycles was noted.
Middle-aged (45-59 yrs.) carcinoma groups also were associated with decreased PR content and

ER function. In those carcinoma groups experiencing the lowest hormone levels and highest ER
content, the ER levels were found to decrease as the estrogen or ratio of estrogen-to-progesterone

blood levels rose. This was in contrast to carcinoma groups with high progesterone levels in
which PR content increased with increasing ratio of estrogen-to-progesterone blood levels (Nikolic-

Vukosavljevic, 1996).
Another study involving 33 premenopausal women noted changes in ER and PR content in
uterine tissue during the cycle with maximal concentrations of both receptors occurring in mid- to

late proliferative phase. Whereas ER declined throughout the secretory phase, PR had complex

dyssy nchronous 11 actuations during the same phase. In the glandular epithelium, PR content
decreased dramatically. In the stroma and myometrium, however, a significant amount of PR was
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maintained. Alterations of receptor content as evidenced here may be one method of regulation in
steroid-dependent growth and differentiation in target tissues (Lessey, 1988).
Estrogenic control of progesterone receptor transcription is yet another manner in which the

hormone environment has an impact on tissue growth and differentiation in hormone responsive

cells. In the rat PR gene there are multiple, widely spaced EREs capable of weak but detectable ER-

ERE binding (Kraus, 1994). Estrogen treatment stimulates PR synthesis alone or synergistically
with serum components insulin and the insulin-like growth factor-1 (IGF-I) (Katzenellenbogen,
1990). This increase in PR levels is due to estrogenic stimulation of the rate of synthesis rather

than affecting PR's rate of degradation (Nardulli, 1988). The estrogen receptor's transcription
activation function-1 (TAF-1) is not required for estrogen regulation of PR gene transcription,
although TAF-2 apparently is needed (Savourel, 1994).

Induction of the progesterone receptor gene can also be accomplished in hormone-free
conditions with the addition of agents w hich increase intracellular cyclic 3', 5'-adenosine

monophosphate (cAMP) levels. Maximal enhancement of PR levels was seen upon treatment with

micromolar concentrations of 8-bromo-cAMP (8-Br-cAMP), and this stimulation was negated by
subsequent addition of the cyclic nucleotide-dependent protein kinase inhibitor H8 or the protein

kinase A inhibitor PKI (Aronica, 1991). The effect of 8-Br-cAMP on ligand-independent
transactivation was more pronounced for the human PR A isoform (hPR-A) than for the B isoform

(hPR-B). Furthermore, 8-Br-cAMP treatment with or without synthetic progestin R5020 down-

regulated lex els of hPR-B in COS-1 monkey kidney epithelial cells with only marginal effects on
hPR-A levels. This suggests phosphorylation may differentially regulate activity of PR isoforms

which themselves apparently operate as distinct regulators of differentiation and proliferation
(Kazmi, 1993).

An increase in PR expression can manifest itself as increased transactivation as evidenced
by a 3-4-fold increase in PR-mediated gene transcription upon dual treatments with progestins and

8-Br-cAMP or okadaic acid. Again this stimulation was abrogated with co-trealmcnt of H8.
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Although progestins cause a 2-fold increase in phosphorylation of receptor isoforms hPR-A and B,
neither 8-Br-cAMP, okadaic acid, nor H8 changed the total 32p labeling of PR nor were

responsible for phosphorylation of receptor resulting in a slower migrating species on sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) mobility assays. Apparently

cAMP-dependent phosphorylations affecting PR transcriptional efficiency involve other integral
proteins or are on key sites of the PR and are not represented as a change in total phosphorylation

(Beck, 1992).
What role phosphorylation of PR plays in transact!vation of the receptor is under

considerable investigation. In one study in which hPR was overexpressed in Spodoptera
frugiperda (SIP) insect cells using the recombinant baculovirus system, it was determined that

hormone-induced PR phosphorylation was not responsible for PR upshifts on SDS/PAGE

mobility assays, nor did it impact on receptor-DNA binding (Christensen, 1991). Data from

Horwitz and co-workers supported Christensen's finding that hormone-induced phosphorylation

was not necessary for nuclear binding. They reported that within 15 minutes of translation both
PR isoforms could undergo transformation and bind DNA with accompanying secondary
phosphorylation. Horwitz et al. did, however, provide evidence that the slower, hormone-

induced phosphorylation step was responsible for migration differences for the 114-, 117-, and
120-kDa PR-B species (Sheridan, 1989).
Phosphoamino acid analysis of PR from the human breast cancer cell line T47D revealed

phosphorylation occurred on serine, but not on tyrosine or threonine residues. lOnM progesterone
treatment increased PR phosphorylation 2-fold in contrast to treatment with epidermal growth

factor (EGF), the Protein Kinase C stimulant 12-O-tetradecanoylphorbol-13-acetate (TPA), or
dibutyryl cAMP, which did not significantly affect phosphorylation of PR (Rao, 1987).
Phosphorylation of serine residues in the chicken oviduct PR w as found to be important in
regulating both basal and hormone-induced activity. Basal activity occurred when Ser-211 and Ser260 were 209£ phosphorylated and Ser-530 dephosphorylated. Hormone treatment resulted in a
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1.5- to 2-fold increase in phosphorylation of Scr-211 and -260 and a greater than 33%
phosphorylation of Ser-530 (Bai, 1994). The cAMP-dependcnt protein kinase is known to
phosphorylate Ser-528, and the catalytic subunit of this kinase mimicked the hormonally-induced

increases of serine phosphorylation (Denner, 1990).
This increase in serine phoshorylation is in agreement with studies of O'Malley and coworkers in which chicken PR phosphorylation increased on 3 sites in response to hormone,

causing a change in receptor mobility on SDS/PAGE gels. This phosphorylation, however, was
strictly dependent on double stranded DNA and was thought to be accomplished by a DNA-

activated protein kinase similar or identical to one isolated from nuclei of HeLa cells, a human
cervical carcinoma cell line. This series of DNA-dcpendent phosphorylations may be required for

PR activation, by-passing hormone requirements as noted in in vitro transcription assays (Weigel,
1992).

Additional sites of senne phosphory lation were noted in human PR and their function

tested in 4 sets of serine to alanine substitution mutants. Mutation of 3 sites, Ser-190 at the aminotcrminus of PR-A, a cluster of serine residues just upstream of the DNA-binding domain (DBD),

or Scr-676 in the hinge region in the B-upstream segment (BUS) inhibited transcription by 20-50%
in a promoter- and cell-specific manner. Mutation of 10 serine clusters located in regions common
to PR-A and PR-B and mutations of 6 serines peculiar to BUS, however, did not diminish the
transaclivation function of either the full-length hPR-B or the construct BUS-DBD-NLS in which
the TAF-3 function of the B-upslream segment (BUS) was fused to the DNA binding domain
(DBD) and the nuclear localization signal (NLS) of hPR. These data suggest that phosphorylation

does not affect transaclivation mediated by TAF-1 or TAF-3, but may act on the transcriptional
machinery distinguishing the A and B isoforms of hPR (Takimoto, 1996).

Intrigued by the presence of multiple isoforms for the human progesterone receptor.
researchers have sought to delineate specific functions for these proteins. It appeal's that hPR-B

behaves as a typical transcriptional activator of progestin-inducible genes, whereas hPR-A can
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function as a transcriptional inhibitor or activator, depending on the context. hPR-A was shown to
repress hER-mediated transcriptional activity in a manner largely dependent on absolute expression
levels of hPR-A rather than hER (Wen, 1994). The A isoform hPR protein can also inhibit hPR-Binduced gene activation. In promoter and cell contexts where hPR-A was inactive, it functioned as

a strong trans-dominant repressor of hPR-B. Although hPR-A did not repress vitamin D receptor
function, it did inhibit transcription induction by classical steroids glucocorticoid, androgen, and

mineralocorticoid receptors. The trans-dominant effects of hPR-A were also observed using a

DNA-binding defective hPR-A mutant (Vegeto, 1993). PR-A repression apparently, then, does

not require direct interaction with chromatin, but as in the case of hER-mediated repression,
involves noncompetitive interaction of the receptor with distinct contact sites or separate cellular
targets. Using two breast cancer cell lines independently expressing only B- or A-receptors, Miller
ct al. demonstrated that R5020-stimulation of flavin-containing monooxygenase 5 (FMO5)

occurred only in PR-B cells with A-receptors again being inhibitor.’ (Miller, 1997).
Differential effects of hPR-A and -B on estradiol-dependent transcription were also
reported by Chai bos and co-workers. Treatment with the synthetic progestin R5020 potently

suppressed estradiol-induced levels of pS2 and cathepsin D mRNA, but unlike Wen's report,
occurred only in cells expressing hPR-B. PR-B transrepression was dependent on promoter

context, but PR-A w as ineffective regardless of the reporter construct used. When both isoforms
were equally present, PR-B was dominant, maintaining >70% inhibition. Unlike hPR-A-mediated
repression, hPR-B apparently acts on the estrogen receptor to repress itsTAF-2 activity (Chalbos,
1994).

hPR-A and -B also behave differently when occupied by progesterone antagonists. In

HeLa cells co-transfected with a PRE-tk-CAT reporter and hPR-B expression vectors, strong

transcriptional activity occurred upon PR activation with either agonist (R5020) or antagonist
(RU486, ZK112993, or ZK98299). Antagonist-induced transcription was PRE-independent but

did require a functional DNA-binding domain (DBD) on hPR-B. hPR-A was not activated when
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occupied by antagonists. Furthermore, when co-expressed with hPR-B, the A-isoform worked in
a dominant fashion to annul the inappropriate activation of hPR-B by antagonists (Tung, 1993).

One explanation for these different isoform-dependent behaviors may be the additional
transactivation function, TAF-3, located in hPR-B's B-upstream segment (BUS). Similar to

antagonist-activated PR-B activity, BUS-DBD-NLS constructs require an intact hPR DBD to
strongly and autonomously activate transcription. In a promoter- and cell-dependent manner,
TAF-3 can activate transcription autonomously or synergistically act with TAF-1 and TAF-2. It is

the autonomous TAF-3 function that may be responsible for anti progestin-occupied hPR-B’s
stimulation of gene expression (Sartorius, 1994).
Differences in phosphorylation of hPR-A and -B were also questioned as possible means
of receptor regulation. In hormone-free conditions 8-Br-cAMP was found to amplify hPR-A-

mediated transact!vation more strongly than that of hPR-B's. 8-Br-cAMP +/- R5020 downregulated hPR-B levels in COS-1 cells while only marginally affecting hPR-A content.

Apparently, then, phosphorylation can indeed affect differentially the activity of these two isoforms
(Kazmi, 1993).
In "normal" PRE-dependcnt transactivation it was questioned as to whether or not

differences also occurred in the interaction of A- and B-receptors with the chromatin. Edwards and
co-workers reported equal enhancement of PR-DNA binding by the high mobility group chromatin

protein HMG-1. Because HMG-1 recognizes distorted DNA structures and can cause further
distortion by bending DNA, it is possible that HMG-1 enhancement of PR binding occurs via

structural alterations in target DNA (Prendergast, 1994).
Follow-up work by Prendergast el al. on the ability of hPR-A and -B to bend target DNA
revealed manv similiarities. Both PR isoforms induced substantial distortions with directional
bends tow aid the major groove of the DNA helix. The apparent bend centers w ere similarly

located a few basepairs from the middle of the PRE. Both the calculated distortion angles and
directed bend angles, however, were greater for hPR-B than for - A. The greater transcription
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activation potential of hPR-B may be linked, then, to its more pronounced effect on DNA structure

(Prendergast, 1996).

That liganded PR acts in remodeling chromatin during transcriptional activation is

supported by the observation that the coactivators SRC-1 and CBPare required for PR
transactivation. SRC-1 and CBP have histone acetyltransferase (HAT) activity, bind to
themselves, and recruit other HAT factors to target promoters. Inhibition of histone deacetylase

strongly pontcntialed PR-mediated transcription (Jenster, 1997). Together these data suggest
liganded PR acts ultimately, as does the ER, to de-repress chromatin and facilitate assembly and
stabilization of the transcriptional machinery.

Understanding the molecular dynamics of gene activation provides the basis for
comprehending cell grow th, differentiation, normal cell death, and ultimately, even their
dysregulation as seen in cancer. One proto-oncogene intimately involved in all four parameters is c-

myc. Mishaps with expression of this proto-oncogene have been reported in Burkitt's lymphoma
(Hann, 1988; Klein, 1983), small cell lung cancer (SCLC) (Nau, 1985; Ou, 1996), and in a

preponderance of primary breast cancer tumors (Varmus, 1982). So, what is this protooncogene's function? How does it work? How is it regulated? And, could steroid hormones

affect its behavior?
The human c-myc gene encodes two functional polypeptides, Myc-1 (439 amino acids (aa)

with an apparent molecular weight, Mr, of approximately 65,000) and Myc-2 (453 aa, Mr of
approximately 68,000). These proteins do not arise from post-translational interconversions, but
are derived from alternative translational initiations at exons 1 and 2 of mvc mRNA. (Hann, 1988)

A third polypeptide, mycHEX 1, only 188 aa in length and of unknown function, arises from a
nonconventional start codon further upstream in exon 1 which was previously thought not to be
translated (Gazin, 1986; Dedieu, 1988). Myc-1 and -2 contain domains common to transcription
factors, namely the leuzine zipper (LZ) (Landschulz, 1988) and helix-loop-helix (H-L-H) domains

(Murre, 1989), a helical stretch of basic amino accids termed the basic region (BR) (Agre, 1989),
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and a nonapcptidc nuclear localization signal (NLS) (Dang, 1988). The H-L-H and LZ motifs arc
required for Myc dimerization with Mye's partner protein Max ("myc Associated X"), whereas the
BR of Myc is required for the Myc-Max hctcrodimers to bind DNA (Blackwood, 1991).

Although Myc is involved in cell cycle regulation during Go-Gi transition and entry' into S

phase, its mRNA expression is not restricted to any phase, but rather, is maintained in

continuously proliferating cells (Thompson, 1985). Levels of Myc protein rise rapidly within the

first 2 hours of Gj upon mitogenic stimulation, are maintained throughout Gj, and then return to
basal levels for the remainder of cell cycle progression. Thompson and co-workers have reported

that c-myc mRNA transcription remains constant throughout the cell cycle, even in density-arrested
cells supplied with serum growth factors (Thompson, 1985). Not only is the synthesis of Myc

protein maintained during all cell cycle phases, but the half-life and modification of c-myc proteins
likewise remain constant both in normal and transformed cells (Hann, 1985). mRNA levels

naturally do decline upon removal of serum and upon cells reaching confluency. Dean and co
workers have reported that this effect on steady stale mRNA levels occurs without affecting the

lex el of transcription, suggesting post-transcnplional control also exists (Dean, 1986a). The c-myc

gene is down-regulated after growth ceases and with the onset of differentiation (Spencer, 1991).
Platelet-derived, epidermal, fibroblast, and transforming growth factors (PDGF, EGF,
FGF, TGF-a, and TGF-p (in mink lung epithelial cells)) promote transcriptional initiation of cmyc in various cellular contexts. (Kelly, 1983; Cutry, 1989; Skouteris, 1992; Sutherland, 1992;
Paterson, 1995; Kim, 1991) Insulin and IGF-1 (Gai, 1989; Banskota, 1989), IL-2,

phytohemagglutinin (PHA) and 12-O-tetracedanoyl phorbol-13-acetate (TPA), as well as

ionomycin (Lindsten, 1988; Reed, 1985; Reed, 1986), Concanavalin A, lipopolysaccharide
(Kelly, 1983), pregnant mare serum gonadotropin (PMSG) (Delidow, 1990), erythropoietin (Li,

1996), dsRNA (Mundschau, 1995), adrenocorticotropin hormone (ACTH), dibutyryl cAMP (in
adrenal tissues), and the protein synthesis inhibitor cycloheximide (Liu, 1996) also promote c-myc
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expression.

Other grow th factors, TGF-[3 (Pictcnpol, 1990; Paterson, 1995) and the tumor necrosis
factor-a (TNF-a), plus dibutyryl cAMP (in HL-60 cells) (Kronke, 1987) down-regulate c-myc via

inhibition of transcriptional initiation. Blocks to transcriptional elongation is another way in which
reagents limit Myc protein production. Substances operating via this route include retinoic acid
(Ou, 1996), 1,25-dihydroxy vitamin D3 (Hulla, 1995; Simpson, 1987), dimethylsulfoxide

(DMSO), a potent inducer of granulocytic differentiation (Eick, 1986), and PKC inducers 1,2dioctanoylglycerol and phorbol 12,13-dibutyrate (Salchi, 1988).

Multiple levels of regulation of c-myc expression tightly control the amount of the gene
product Myc. Myc protein expression is regulated at the level of transcriptional initiation and
elongation, posttranscriptionally by different portions of the c-myc transcript affecting message

stability, at the level of translation, and by post-translational modifications as well (Marcu, 1992).
The function of Myc protein is only beginning to be elucidated.

The Myc protein acts as a sequence-specific transcription factor when bound as a

heterodimer to Max, a basic region, hclix-loop-helix, leucine zipper [(BR)H-L-H(LZ)] protein of
160 amino acids (Blackwell, 1990). Myc's ability to function also as a DNA replication factor was

suggested by experiments in which treatment with c-myc antisense oligonucleotides prevented

entry of cells into the S-phase of the cell cycle (Heikkila, 1987). Binding of the Myc/Max protein
complex to a 7bp sequence in the regulator} region upstream of the first exon of the c-myc gene

was shown to be indispensable to both maximal ori and enhancer activities (Ariga, 1989), again
suggesting a role for Myc in regulation of DNA replication.
Evidence for Myc’s role as a transcription factor binding specifically to CACGTG

sequences in the DNA (Blackwell, 1990) came with demonstration of Myc/Max binding to the 5’
upstream region of the dihydrofolale reductase gene (DHFR). DHFR is a key enzyme in folate
metabolism supplying the cells with dTTPs necessary for DNA synthesis (Mai, 1994). Myc can
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also suppress genes as was noted in its repression of CCAAT/cnhancer-binding protein cc-gcne
(C/EBPez) expression through interactions with the core promoter region (Antonson, 1995).

Another way in which Myc protein may impact on growth in breast cancer cells is via

interaction with other transcriptional regulators including Yin-Yang-1 (YY1) which itself behaves
as transcriptional activator, repressor, or initiator depending on cellular context. Binding of Myc

protein to YY 1 completely inhibited YY I's repression of thymidine kinase in reporter constructs

(Shrivastava, 1993). Myc has also been shown to inhibit activity of TFII, another transcriptional

initiator (Roy, 1993). Myc can also bind the TATA-binding protein (TBP) of the TFIID
transcription initiation complex (Maheswaran, 1994), thereby enabling Myc regulation of growth
processes at the level of the basal transcriptional machinery'.
The Myc protein can bind a regulatory region upstream of c-myc's own exon 1 to

positively regulate its own expression (Ariga, 1989). Il is also regulated in a cell- and promoter
specific fashion by other oncogene products. Early transforming proteins of the polyoma virus

cause increases in c-myc transcripts (Zullo, 1987), as does c-myb expression (Evans, 1990;

Cogswell, 1993). v-abl in a myeloid cell line upregulated c-myc transcriptional initiation
(Birchenal-Roberts, 1996), but in a fibroblast line was responsible for amplified c-myc loci with
concommitant transcriptional blockage resulting in reduction in Myc protein (Nepveu, 1985). cA bl is a nonreceplor protein tyrosine kinase which increases expression of c-myc reporter

constructs, likely via in teraci ton with other DNA binding proteins (Arcinas, 1994). In mice

adrenal glands, kidneys, and splenic B cells, but not in heart, liver, thymus, brain, and lung, c-Abl
can directly transactivate c-myc transcription (Wong, 1995). Other tyrosine kinases, fms, sre, and
trk, cooperate in promoting constitutive myc expression (Cleveland, 1989). v-raf and fos/jun

complexes, however, negatively regulate myc (Zullo, 1988; Hay, 1989). The rel-oncogene-rclated

family of NF-kB factors have differential effects on the c-myc promoter. Classical NF-kB
potently activated c-myc transcription unless co-expresscd with v-rel. v-rel itself or chicken c-rcl
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did not affect transcription whereas murine c-rel had a slight stimulatory’ effect (La Rosa, 1994).
Conflicts in reports over myc regulation by TGF-(3, di butyryl cAMP, and v-abl, plus others not

noted here indicate that cellular physiology impacts greatly on signaling pathways responsible for

growth regulation.

Steroid hormones estrogen, progesterone, glucocorticoids, and retinoic acid, as noted
previously, also affect c-myc regulation. Growth inhibitory effects of glucocorticoids in lymphoid
cells involve down-regulation of myc (Rhee, 1995) at the level of transcriptional initiation

(Forslhoefel, 1987). In glucocorticoid-treated fibroblast cells, however, inhibition of proliferation

did not involve regulation of either c-myc mRNA or protein (Frost, 1994). These experiments
demonstrate the importance of cellular context for the role of c-myc in regulation of cell

proliferation.
Stimulation of growth in the human breast cancer cell line MCF-7 by estrogen is supported

by rapid induction of c-myc, independent of protein synthesis (van der Burg, 1989). Estrogenic
stimulation in MCF-7 cells of the myc gene is exclusively at the level of transcription (Dubik,

1988). Although a consensus ERE was not identified, a 116-bp region encompassing the TATA
box of the P2 promoter was found necessary for eslrogen-mediated regulation of c-myc (Dubik,

1992). In normal human breast epithelial (HBE) cells, lOnM estradiol elicited a biphasic increase
in c-myc mRNA lex els with the first peak at 30 minutes and the second at 2 hours post-treatment.
This stimulation again was found to be al the transcriptional level (Leygue, 1995). In male Wistar
rats administration of estradiol resulted in increased c-myc mRNA levels in their anterior pituitary

glands. Occurring with estogen-induced c-myc stimulation was transcription of the prolactin gene
(Szijan, 1992).
The effect of progestins on c-myc expression in the breast cancer cell line T47D is

complex. Initially, synthetic progestins were reported to cause a rapid but transient induction of cmyc, a transient acceleration of cells already in Gi of the cell cycle through its cycle of replication,
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and cellular arrest in the following cycle with subsequent growth inhibition (Musgrove, 1991).

Treatment of T47D cells with progestin medroxyprogesterone acetate caused a 2-fold increase of cmyc mRNA levels, followed by a decrease, and then partial recovery' (Wong, 1991). Both these
groups, however, reported that progestin inhibited cell growth. A possible mechanism whereby

the progesterone receptor itself could repress the c-myc promoter has been postulated for the avian
oviduct system. A 54-bp receptor-binding factor (RBF)-binding element located between dual
matrix-associated regions of c-myc's P2 promoter provides a unique chromatin/nuclear matrix

structure which can bind the PR (Laubcr, 1997). Occupation of this [3-sheet structure could cause

DNA confomational changes so as to disrupt normal processing by transcriptional machinery.
Although progesterone was reported to be repressive in the growth of breast cancer cells by
numerous investigators in previous decades (Horwitz, 1985; Chalbos, 1982; Lippman, 1976), data

from Moore and co-workers and others demonstrated stimulation in these cell lines (Hissom, 1989;
Moore, 1991; Manm, 1987; Robinson, 1987; Longman, 1987). A major contribution to

reconciliation of these conflicting reports was Katzenellenbogen's discovery’ of estrogenic
properties of phenol red, a pH indicator routinely included in cell culture media (Berthois, 1988).

Variation in experimental conditions, in the quantity and quality of serum's constituents, growth

factors, trace hormones, and as-of-yet still undefined components of signaling pathways, is

increasingly recognized as critical in defining cellular context, and ultimately, the observed
response (Moore, 1981; Welshons, 1992). The modification of Horwitz's stance on progestins'

relation to breast cancer growth exemplifies the evolution of the research community in grappling
with the many elusive factors affecting growth regulation (Groshong, 1997).

Since the mid-80's Moore and co-workers have rigorously maintained that progestins could
and did behave milogenically in T47D breast cancer cells (Hissom, 1987; Hissom, 1989; Bowden,

1989). In trying to unravel the mechanism(s) by which progestins stimulate growth, these

workers have examined various elements that might be involved in this response. Correlative
increases in lactate dehydrogenase (LDH) activity upon progestin treatment were examined
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(Hagley, 1987) but were found to be dependent on RNA and ongoing protein synthesis, and thus
were not due to direct gene activation by this hormone. This was also true for the dose-dependent

elevation of thymidine kinase activity witnessed upon progestin stimulation in T47D cells (Moore,

1991). A possible gene target for progesterone-mediated growth stimulation would be a
protooncogene involved in immediate early responses to mitogen such as c-myc.
We have hypothesized that progestins elicit a growth response, in part, due to direct

activation of the c-myc gene. To test this hypothesis a series of experiments was proposed in
which we examined levels of c-myc mRNA following treatment with the synthetic progestin

R5020. They are as follows.

T47D cells were treated with R5020 at various concentrations to determine optimal dosage
and for various lime intervals to pinpoint the treatment time for maximal response.

Co-treatmenl with the antiprogestin RU486 was done to assess more clearly whether or not

stimulation of c-myc was likely operating through PR-mediated pathways. Earlier, Moore and co

workers had uncovered concentration-dependent growth agonist activity of RU486, establishing
RU486's dual potential as antagonist/agonist. (Bowden, 1989) In our experiments the
concentration of RU486 was kept well below the growth agonist-associated concentration.

The possi billy that progestins stimulated c-myc via a nonspecific steroid mechanism was

addressed by comparing c-myc induction by members of each of the five classes of steroid
hormone at a physiologically relevant concentration of 10 niM. This experiment also allowed us to
determine what other hormones might stimulate myc under our experimental conditions. Dubik and

Shin had reported estrogen stimulation of c-myc in the ER-positive cell line MCF-7 (Dubik, 1988),

and reports conflicted over glucocorticoids1 ability to transact!ve the c-myc gene (Forsthoefel,

1987; Frost, 1994). These hormones have not been tested for their effect on c-myc gene
expression in T47D cells.

To determine whether or not the synthesis of new proteins was required to elicit progestinmediated changes in c-myc mRNA levels, pre- and co-treatment with the protein synthesis inhibitor
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cycloheximide (CHX) was performed. Preliminary experiments were conducted to determine the
cycloheximide dosage, as well as the duration of exposure and treatment regimen, required to

inhibit at least 90% of protein synthesis. Viability of cells was initially checked at a much higher
dose of CHX than what was eventually used in the actual experiments. This check, however,

allowed us to verify that any reduction in protein synthesis observed was not simply due to cell

death.
Increases in mRNA levels can be due to enhanced transcription, reduced degradation, or a

combination thereof. Stabilization of transcripts results in a longer half-life for the message and is

a common mechanism by which mitogens operate. To investigate if R5020 was indeed protecting
c-myc mRNA from degradation, transenption was halted for various lengths of time in both

control and hormonc-treated cells with the addition of the inhibitor actinomycin D after 1 hour of
R5020/control exposure. By blocking elongation, actinomycin D eliminated production of any
new transcripts, so that the relative levels of c-myc mRNA over time were indices of message

decay. Information from the graph of these data was used to determine c-myc mRiNA's half-life in

both control and R5020-treated cells. A change in mRNA stability could be responsible for
observed differences in mRNA levels, but would not preclude hormonal enhancement of

transcription.
To specifically address progestin activation of transcription, nuclear run-on assays are

needed. In this assay the nuclei of treated cells are isolated. Within these nuclei are the genes that
have been transact!valed and a limited number of pre-mature mRNA transcripts that have yet to be

exported to the cytoplasm. Elongation of already initiated transcripts is the only source of
quantifiable c-myc levels. The nuclei are treated with a cocktail in which one ribonucleotide is

radioactivcly labeled, thereby providing a tag for freshly transcribed mRNA species. This mRNA
is isolated and quantitated as detailed in Materials and [Methods. Any differences in newly
synthesized mRNA levels from control versus R5020-treated cells would reflect effects on the rate

of transcription. This experiment was conducted but did not yield conclusive results.
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MATERIALS AND METHODS

Preparation of all solutions/reagents are detailed in the Appendix.

The manufacturers of reagents, supplies, and equipment are also listed therein.

Cell Culture:

T47D wild type cells were obtained from the American Type Culture Collection. They
were grown in Gibco-BRL growth medium (see below) in polypropylene tissue culture flasks

(75cm- - 175cm-) with canted necks in air containing 5% COo at370C. Cells were harvested by
replacing the growth medium with "splitting solution", i.e. Hank's balanced salt solution without
calcium and magnesium but with ImM ethylenediamine tetraacetate (EDTA), incubating 10

minutes at 370C, agitating the cells free, and centrifuging the cells to store as a pellet at -85°C.

Cells were passaged weekly upon reaching a confluency of 60-70% using the "splitting solution"
as above, replacing 15% of the cells into the same culture flask. After a total of 5 passages, a fresh
culture flask was used.

RNA Isolation:
Total cellular RNA was isolated using a slightly modi lied version of Chomczynski and

Sacchi's Single Step method (Chomczynski, 1987). Cell pellets, stored in 50ml disposable
centrifuge tubes, were retrieved from the -85°C freezer, placed on ice, and maintained thereon

throughout the benchtop procedure. Solution D (1 ml/107 cells) was added to the frozen pellets

and vortexed al full speed for one minute. Care was taken to ensure that the cell pellet was

completely dissolved at this point. 2M sodium acetate (NaOAc) pH 4.0 (0.1 ml/107 cells) was
added, and the 50ml centrifuge tube was inverted 5 limes to ensure mixing. Water-saturated
phenol (1.0 ml/107 cells) was then added, and the mixture was again inverted 5 times. Next, 49:1

chloroform:isoamyl alcohol (0.2 ml/107 cells) was added and the mixture shaken vigorously for 10
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seconds. The cells were then cooled on ice for 30 minutes during which lime the cell mixtures
were transferred to clean autex:laved 15ml Corex tubes. The Corcx tubes were centrifuged at
10,000 x g (9100 rpm in JA-20 rotor, Beckman J21-C centrifuge) for 20 minutes at40C. The

upper aqueous layer was transferred with sterile Pasteur pipets into clean autoclaved 15ml Corex

tubes. An equal volume of isopropanol was added, vortexed gently to mix, and then placed at

-200C with the tubes covered with parafilm for an incubation of not less than 1 hour. Typically the
RNA was allowed to precipitate for 4-6 hours before proceeding. Following the incubation, the
Corex tubes were centrifuged at 10,000 x g for 20 minutes at 4°C. The pellet was dissolved in

Solution D (1.0 ml/107 cells). One volume of isopropanol was added, mixed, and the tube
returned to -20°C for an incubation of at least one hour. When the volume of Solution D was less
than 1 ml, the resuspended pellet was transferred to autoclaved 2ml microcentrifuge tubes and

precipitated with 1 volume of isopropanol. This allowed for greater ease of handling. Often the

precipitation was allowed to proceed overnight. The tubes were then centrifuged at4°C for 10
minutes at 10,000 x g for Corex lubes or 15,000 x g for 2ml microcentrifuge tubes. The pellets
w ere resuspended in ice-cold 75% ethanol (1.0 ml/107 cells), spun again as above, and the pellet

was dried in vacuo in a desiccator (Corex tubes) or in the Savant Speed-Vac SCI 10
(microcenlrifuge tubes). Care was taken not to over-dry the pellet as this would make
resuspension very difficult. The final RNA pellet was resuspended in 0.1% diethyl

pyrocarbonate-treated water (DEPC-HoO) to approximate a concentration of 3.3 mg/ml or higher.
RNA concentration was determined by absorbance at 260nm (A260) in a lcm pathlength

cuvette where concentration equals (A260) (40 ug/ml) (total sample volume in cuvette, ml)
(volume of RNA , ul, added to the sample volume)-1. The RNA was aliquotled into 20-25 tig

samples for gel electrophoretic separation. These were used immediately or precipitated with 0.1

volume of 3M NaOAc pH 5.2, plus 2.2 volumes of absolute ethanol and stored at -20°C.
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RNA Dot Blots:
Prior to use, the Bio-Rad Bio-Dot Microfiltation Apparatus was cleaned with 0.IM NaOH,
rinsed with deionized distilled waler then with DEPC-H2O, and air-dried in the sterile hood. The

nylon membrane was cut to the size of the manifold, 9 x 12 cm-, and soaked in 10X SSC for at

least 10 minutes. The apparatus was assembled per Bio-Rad instructions. Wells were filled with
100 id 10X SSC and left undisturbed w hile the RNA samples were prepared.

RNA samples were denatured with addition of 3 volumes of RNA Denaturing Solution (see

below), incubated at 65°C for 15 minutes, and quick-chilled on ice. Two volumes of ice-cold 10X

SSC were added to the RNA. Samples were centrifuged briefly to collect contents.
Vacuum was applied to the Bio-Dot apparatus until the 10X SSC was pulled through. The
RNA samples were loaded, any empty wells receiving 10X SSC, and the vacuum reapplied. All

wells were then filled with 10X SSC, 0.735ml volume, and suctioned through. This was repeated
once. The apparatus was then dismantled. The wet nylon membrane was marked with pencil to
identify the RNA samples, placed on Whatman 3MM filter paper to air-dry for at least one hour,

and UV cross-linked at 1200Hz on model UVP CL-1000 cross-linker. Membranes were stored
sandwiched between pieces of 3MM Whatman paper, w rapped in aluminum foil, and placed in a

lab bench drawer.
RNA Gel Electrophoresis:
The gel, 100 ml of 1% agarose in 2.2M formaldehyde, IX MOPS buffer solution, was

poured into a BRL Horizontal 11.4 gel box and allowed to polymerize at least 30 minutes before
covering with 750 ml IX MOPS buffer.
RNA samples were prepared in autoclaved 1.5ml microcentrifuge tubes, 20 ug RNA in 20

id final volume of deionized formamide (50% v/v), 2.2M formaldehyde, IX MOPS builer. An
RNA ladder (2 id) and 10-20 iig of representative sample RNA were prepared as above to be run
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in lanes 1 and 2 on every gel. All RNA samples were denatured at 65°C for 5 minutes and
quick-chilled on ice. Prechi lied Gel Loading Buffer (2u.l) was added to each sample, mixed by
pipcting, and the samples were briefly centrifuged to collect sample prior to loading onto the gel.
Electrophoresis was accomplished by applying 70 volts to the 14 cm gel (5 volts/cm) until

the dye front had migrated 2/3 down the gel. The gel was rinsed 10 minutes with shaking in 200
ml of 0.1% DEPC-HoO. Lanes 1 and 2 containing the RNA ladder and the representative sample
were cut from the gel, soaked 30 minutes in ethidium bromide solution (5 ug/ml), placed in

200-300 ml deionized water to destain for 6-12 hours, and then viewed at300nm on the Fotodyne
UV light box to verify RNA integrity and location of the 18S and 28S rRNA. The rest of the gel

was rinsed an additional 45 minutes in 10X SSC with shaking prior to transfer to a nylon
membrane. Transfer in 10-20X SSC was accomplished either by downward or upward capillary

action (sec below). After transfer was complete, the wet nylon membrane was marked with a
pencil to identify the preparation and the location of sample lanes. The nylon membrane was
air-dried 1 hour, then UV-cross-linked al 1200 Hz on model UVP CL-1000 cross-linker. The

membrane could be stored sandwiched between 3MM Whatman paper, protected in aluminum foil
wrap in the lab bench drawer, or utilized immediately in Northern blot hybridization.

Downward capillary transfer:
A cellulose sponge purchased from local vendors was prepared for usage in Northern

blotting as follows. The sponge was rinsed 15 minutes in tap water with repeated wringing to
ensure maximum purging of manufacturer's chemicals. It was then boiled in deionized water for

20 minutes, followed by 2 minutes of rigorous rinsing in deionized water. The sponge was then

soaked in 300 ml of water for 20 minutes, removed and wrung dry, and then left to air dry atop a
plastic test tube rack.
In a shallow plastic dish a slack of paper towels was placed, 2-3 cm high, folded in a

rectangle. On top of the paper towels was placed 3MM Whatman filter, cut with the same

32

dimensions as the nylon membrane, presoaked in 10X SSC. Directly centered on lop of the
blotting paper was a nylon membrane, glossy side down, cut with dimensions slightly larger than

the gel's and presoaked in 10X SSC for at least 10 minutes. The agarose gel was gently applied
to the top of the nylon and covered with two 3MM Whatman filters, presoaked in 10X SSC and of

the same size as the gel. Any bubbles were removed by rolling a glass stirring rod along the

surface after each layer was applied. Plastic wrap framed the top blotting paper, extending to cover

the edges of the plastic dish, to provide a barrier against undirected saturation of the transfer

apparatus. Finally, a cellulose sponge, thoroughly rinsed of all chemical reagents, then saturated
in 10X SSC, was centered on top of the plastic wrap-framed blotting apparatus and covered itself

with a sheet of plastic wrap to minimize evaporation (Zhou, 1994). Transfer was allowed to
proceed for a minimum of 6 hours, but frequently overnight.
Upward capillary transfer:
A blotting support was constructed in a plastic tray (10 x 12 x 2.25 inches) in which

700-900 ml of 20X SSC were placed. A plastic pipet lip holder, used as a "stage", was centered

in the tray and covered with a wick constructed of three 3MM Whatman Filters, 14 cm wide (the
length of the gel) and 13 inches long. Centered on top of the wick, saturated with 20X SSC, was

the nylon Hybond-N membrane, cut exactly the same size as the gel and itself pre-saturated with

20X SSC. Three pieces of 3MM Whatman filter paper, same dimensions as the gel and saturated

in 20X SSC, were placed directly on top of the membrane. Air bubbles were again removed after
each layer was applied by rolling a glass stirring rod along the surface. On lop of Whatman

blotting paper a 5 cm stack of paper towels was placed and weighed down with a glass plate on
which additional weights were positioned. The entire apparatus was then covered with plastic
wrap. Transfer proceeded for 12-16 hours.

Silanization of hybridization bottles:
A 1% (v/v) solution of dimelhyldichlorosilane in benzene was placed in the hybridization
bottles and heated to 60°C in the hood. The lubes were rinsed in the dimelhyldichlorosilane
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benzene solution and then dried in an oven at 60°C. Rinsing and drying was repeated once.

Northern blot analysis:

Fresh prehybridization solution, 175 ul/cm2of nylon, was prepared for each membrane
and incubated with the nylon membrane in pre-treated silanized hybridization bottles in a Robbins
Scientific Hybridization Apparatus. The hybridization bottles were rotated to ensure adequate

exposure of the membrane to the solution. Air bubbles were squeezed from the membrane-glass
interface with a rubber policeman on long glass stir rod. After the incubation temperature reached

the steady hybridization temperature of 42°C, 20 ug/ml denatured salmon sperm DNA was added
to the prehybridization solution (see below). Prehybridization continued for at least 4 hours.
Denatured 32p-iabeled cDNA probe for either c-myc or glyceraldehyde phosphate dehydrogenase

was added to the prehybridization mixture and incubation at42°C continued for an additional
16-30 hours.

The nylon membrane was subjected to a series of washes to remove non-specific binding

of the labeled probe to the nylon. Radioactive solutions were poured into a designated radioactive
waste container and disposed of according to NRC guidelines. First the nylon membrane was
rinsed briefly with 50 ml of 2X SSPE, 0.1% SDS at room temperature, then soaked 10 minutes in

150 ml of the same solution. The second wash was again at room temperature, 200 ml of 2X
SSPE, 0.1% SDS, for 10 minutes. The third wash was al 65°C for 15 minutes in 200ml of IX
SSPE, 0.1% SDS. The fourth and fifth washes were 10 minutes each at 65°C in 200ml of 0. IX
SSPE, 0.1% SDS.
The nylon membrane was blotted on Kim-wipes to remove excess wash solution and then
scaled in plastic "seal-a-meal" bags with an American International Electric impulse sealer at a

temperature setting of 2-3. Care was taken to ensure that the membrane remained moist and that

all air bubbles were removed from the "seal-a-meal" bag. The sealed nylon membrane was then

34

loaded into an autoradiogram cassette in the dark-room with an intensifying screen and a sheet of
unexposed x-ray film on either side. The membrane was secured to the bottom x-ray film with

tape to prevent its movement during exposure. The entire cassette was wrapped in aluminum foil

and placed al -85°C to develop. The time needed for adequate development of the x-ray film was

estimated according to the cDNA probe used and the strength of the signal from the nylon as
measured with a Geiger counter. Exposure time varied from 8 hours to 3 days or more. The

exposed x-ray film was developed, and the intensity of the exposure of the autoradiogram was
analyzed dcnsitometrically.
Each nylon membrane was stripped of the first probe and reprobed with the second probe

to identify mRNA levels of c-myc and of the non-progestin-stimulated mRNA
glyceraldehydc-3-phosphate dehydrogenase (GPDH). Stripping was accomplished by incubating
the membrane twice for 15 minutes each in boiling hot 0. IX SSPE, 0.1% SDS. The nylon

membrane was stored moist in a "seal-a-mcal" bag at 4°C.
Acquisition of cDNA probes:
The probe for c-myc was graciously provided by Dr. Shelly Finver of the Microbiology

Department, Marshall University School of Medicine, WV as the plasmid pRyc7.4 which includes
a 1016 basepair (bp) cDNA fragment (60% of exon 2 and the entire exon 3) of the human c-myc

gene inserted into the Pstl restriction site of plasmid pBR322. This was amplified in the
Escherichia coli strain DH5-a. The probe for GPDH was given by another member of Marshall

University's Department of Microbiology, Dr. Donald Primerano as pRGPDH. The rat GPDH

cDNA fragment, 1233 bp in length, is inserted at the Pst 1 site of pBR322 to produce pRGPDH,
which was then transfected into the E. coli strain NM522. Both of the probes were used as the
short, excised cDNA fragments rather than the entire plasmids. Preparation of NM522 competent

cells and transformation were accomplished by a fellow graduate student, Cathy Sole, and the

transformed NM522 stock cells given to me under Dr. Primerano's direction. Stock colonies of
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both DH5-cc and NM522 were stored in 50% glycerol at -85°C.
Active cultures of these transformed bacteria were streaked onto agar plates of
Luria-Berlani (LB) broth containing 12.5 ug/ml telracycline-HCl, incubated at370C for 10-12

hrs, and then stored at 4°C. Colonies thereon were viable for 4-6 weeks. Individual colonies of
at least 1.5mm in size were selected randomly to be grown for isolation of the plasmid DNAs.
These DH5-a or NM522 colonies were cultured in LB medium supplemented with 12.5 ug/ml

telracycline-HCl (LB+tet) at 370C with agitation for 12-16 hours in Ehrlenmyer flasks. Because

tetracycline is light-sensitive, all medium in which it was included was protected from light.
Several methods were used to isolate the plasmid DNA, including polyethylene glycol (PEG)
preparations, Promcga Wizard and Magic Midi- and Mini-preps, and QIAGene plasmid kits. The

basic procedure called for lysis of the bacterial cells followed by neutralization and centrifugation to
remove genomic DNA. Procedures for isolation of plasmid DNA differed in the marketed kits,

some employing affinity resins in their final purification step. The manufacturers' guidelines were
followed.
PEG_plasmid isolation:

Transformed E. coli were grown in 200 ml sterile LB+tet in an autoclaved 1 liter

Ehrlenmyer flask (E-flask) as described above. The cells were then centrifuged in 250ml Nalgene

bottles at 5000 x g (6K rpm, GSA rotor) for 5 minutes at 4°C and the supernatant discarded into a

bleach-waste receptacle. The pellets were resuspended on ice in 3 ml of freshly prepared ice-cold

lysis buffer (see below) \\ ith an inverted 10ml sterile serological disposable pipet. Frothing was
carefully avoided. The resuspension was transferred to fresh sterile 50ml disposable centrifuge
tubes and set in ice-waler for 10 minutes. Six milliliters of Solution II (0.2M NaOH, 1% SDS)

were added and mixed by inversion, and the tube returned to ice for 10 minutes. Four milliliters ot

the neutralization solution, 3M sodium acetate, pH 4.8, were added and mixed by hard shaking for
2 minutes after which the lube was placed on ice again for 10 minutes. Proteins and genomic
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DNA were centrifuged out of solution al 1 1,000 x g (9.6K rpm in JA-20 rotor, Beckman

centrifuge) for 10 minutes at 40C. The supernatant was transferred to fresh sterile 50ml disposable

centrifuge tubes and centrifuged as above to guarantee complete avoidance of the white precipitate
of proteins and genomic DNA. RNase A (50 ug) was added to the supernatant, and the mixture
incubated for 20 minutes in a 370C water-bath. One volume of 1:1 TE-phenol/chloroform, pH

7.5-8.0, was added and vortexed for 5 minutes to extract plasmid DNA. This was centrifuged at
2000 x g (3K rpm, JA-20 rotor) for 3 minutes at 40C. The upper aqueous layer was transferred to
a fresh sterile 50ml tube, one volume of 24:1 chloroform/isoamyl alcohol added, and the mixture

vortexed 5 minutes. This was centrifuged as above. The upper aqueous phase was transferred to

an autoclaved 30ml Corex tube, mixed with one volume of isopropanol, and placed at -200C for at

least 30 minutes. If precipitation failed to occur with addition of the isopropanol, 0.1 volume of
3M NaOAc pH 4.8 was also mixed to the solution prior to incubation at -20°C. Afterwards, the
preparation was spun at 11,000 x g for 10 minutes al 40C. The pellet was totally dissolved in 0.4

ml sterile water. Next, 0.1 ml 4M NaCl was added and mixed. This was followed by the addition
and mixture of 0.5 ml 13% PEG (w/v). The suspension was placed in ice-water for 1 hour, after
which it was centrifuged al 10,000 x g for 10 minutes at 40C. The pellet was resuspended in 1 ml

ice-cold 70% ethanol, transferred to an autoclaved microcentrifuge tube, and dried for

approximate!}’ 15 minutes at low temperature in the Speed-Vac or until the pellet was no longer wet
but not completely dehydrated. The plasmid DNA was then resuspended in low TE and stored at

40C. Storage al -200C necessitated precipitation with 0.1 volume of 3M NaOAc, pH 4.8, and 2.2

volumes of ethanol.
Labeling_cDNA probes:

cDNA probes were labeled with radioactive 32P (Amersham Redivue) using random
priming kits marketed by Promega or Ambion. Non incorporated nucleotides were removed from

the labeling mixture by passing the mixture over a G-50 Sephadex column. One microliter of the
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eluate was mixed with 249 ul of water for evaluation of percent radioactive incorporation. Five

microliters of this 1:250 dilution was spotted onto a glass fiber filter disc, washed in ice-cold 10%
trichloroacetic acid (TCA)-1 % sodium phosphate solution to precipitate labeled DNA, and then
rinsed three times with 95% ethanol at room temperature. The filter was allowed to air dry,

immersed in 5 ml scintillation fluid, and counted in the scintillation counter. The formula used to
calculate percent incorporation was provided by the manufacturers.
The G-50 Sephadex column was prepared on the day of use in a lec tuberculin syringe.

The plunger was removed and glass wool was used to plug the bottom. G-50 Sephadex slurry
(see below) was pipetted into the upright syringe, taking care to avoid introduction of air bubbles.

The syringe was centrifuged in the clinical centrifuge at 500 X g for 5 minutes to pack down the
Sephadex. Additional Sephadex was added and packed until the column was nearly full. Space for

a 150 ul volume was left vacant at the lop. The column was then equilibrated with 100 ul
equilibration buffer (see below), centrifuging al 500 X g for 5 minutes..
Experiments:

Growth medium was modified to exclude phenol red, and the fetal bovine serum (FBS)

was treated with dextran-coated charcoal (see below) once in initial experiments and twice in later

experiments as this was found to give better results. Cells were plated into culture flasks (75 or
150cm2) so that they covered approximately 15% of the surface area (approximately 1 million cells

per 75cm2) and allowed to grow to 20-30% confluency with at least one medium change before
treatment commenced. Hormones were added in absolute ethanol, and an equivalent volume oi

ethanol were added to control flasks. Approximately 6 million cells per sample were treated at

given concentrations for the limes indicated below. Certain experiments had a pre-treatment
regimen in which the phenol red-free, double charcoal-stripped serum containing medium was
replaced with growth medium that was serum-free, insulin-free, and phenol red-free

(SF/IF/PRFM) for 4 hours prior to and during treatment. At the conclusion of the experiment.
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cells w ere harvested, placed in 50ml disposable centrifuge tubes, centrifuged at 1000 rpm in the
Damon/IEC HN-SII centrifuge at room temperature, and stored at -850C.

R5020 Dose Response:

T47D cells (5.4 x 107) were seeded in 48 T-75 culture flasks and grown in CS—FBS

medium until reaching 20-30% confluency. Medium was changed at least once. On the day of
treatment, cells were pre-treated 4 hours with 14 ml serum-free, insulin-free, phenol red-free
medium (SF/IF/PRFM) and grouped into 8 different paired treatment groups: control plus 10-12M

R5020 to 10'6M R5020. Cells were treated for 1 hour with R5020 or vehicle and then harvested.

Ethanol at a final concentration of 0.1%. was present in all treatments. Each treatment was done in
duplicate.
R5020 Time Course:

T47D cells (9 xlO7 ) were seeded in 46 T-150 flasks in CS-FBS medium and grown until
reaching 20-30% confluency with at least one change of medium. On the day of treatment, flasks

were paired so that each treatment group had approximately the same number of cells. The best

matched 44 flasks were used for the experiment. Treatments were done in duplicate.
In the initial experiment, time points for treatment with 1O8M R5020 were chosen as 5

min., 15 min., 30 min., 1 hour, 2 hours, 6 hours, and 24 hours. Vehicle alone (0.1% ethanol)

was also administered for lime points 5 min., 1 hour, 6 hours, and 24 hours. At the end ot
treatment limes of 1 hour or less, the flasks were immediately placed on ice to prevent further
cellular activity and the cells harvested with ice-cold splitting solution and rubber policemen. For

treatment limes greater than 1 hour, cells were harvested in 370C splitting solution with agitation

and a serological pipet.
Subsequent experiments evaluating optimal treatment times for R5020 were conducted so

that at each lime point, 5 minutes through 6 hours, cells were treated with either 1O8M R5020 or
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vehicle (0.1% ElOH). Harvesting procedures were identical to those outlined above.
Effect of Antiprogestin RU486:

T47D cells (3 x 107) were seeded into 25 T-75 culture flasks or into 17 T-150 flasks and
grown in CS-FBS medium until reaching a conflucncy between 20 and 30%. Medium was
changed al least once. Flasks were grouped, pairs of triplicate T-75's or duplicate T-150's, and

were incubated for 2 hours with one of the following treatments: 1O9M R5020 + 10-5% ethanol
(ElOH), 10-10 MRU486+ 10-4% EtOH, 10-9MR5020 + 10-10 M RU486, or l.lx 10-*% EtOH

in 10% CS--FBS medium. Final concentrations were l.lx 10-4% EtOH in all treatments.
Hormone Specificity:

T47D cells (5 X IO7cells) were divided into 44T-75 flasks. Alternately, approximately 68
X lO^ cells were split among 30 T-150 Basks. Cells were grown in CS2-FBS medium until 20-

30% confluent with al least one change of medium. T-75 Basks were grouped into pairs of
triplicates and T- 150's into pairs of two for 7 different 1 hour treatments, control or 10-8M
hormones: aldosterone, dexamethasone, estradiol, progesterone, R5020, or testosterone. Cells
were incubated 4 hours in serum-free, insulin-free, phenol red-free medium (SF/IF/PRFM) prior
to treatment. Hormone or EtOH was dissolved and dispensed in SF/IF/PRFM for these

experiments. The final ethanol concentration was 0.1% for all treatments.

Cycloheximide viability determination:

Six-well tissue culture plates were seeded at 15% confluency, 1.5 X 10-5 cells per well, in

10% CS--FBS medium and grown to 25-35% confluency with at least one medium change. Two
wells were combined for each of the three treatments: (I) ImM cycloheximide in 0.1% EtOH +
0.1% ethanol, (II) 1 mM cycloheximide in 0.1% EtOH + 10-8M R5020 in 0.1% EtOH, or (III)

0.2% ethanol as the control. Cells for treatments I and II were treated 4 hours with cycloheximide
in 0.1 % EtOH, while control received 0.1 % ethanol for the same 4 hours. Following
prc-lrealment with cycloheximide, the cells were exposed to either an additional 0.1% EtOH lor
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treatments I and III or to 1O8M R5020 in 0.1% EtOH for 1 hour for treatment II. The final EtOH
concentration was 0.2% for all treatments. At the end of this hour all medium was removed, and

2 ml of 0.4% trypan blue solution were added to each well. The cells were incubated at room

temperature for 5 minutes with the trypan blue, after which the stain was removed and the cells
examined under the microscope for uptake of trypan blue, an indicator of cell death (Ausubel,

1995). Four fields of view were randomly selected for each well. The total number of cells were

counted, both those blue with the stain and those still clear. The numbers for each view were

combined for a given well. Percent viability was calculated as 100% minus [(number of blue cells)
divided by (number of total cells) X 100%] for each well. The percent viability was averaged for
the two wells of each of the given treatments.

Cyclohe xi mide__d osage:
Six-well culture plates were seeded at 10% confluency, 9 X 104 cells per well, in

serum-free, phenol red-free medium (SF/PRFM) and grown to 25-30% confluency. Cells were
then treated for 30 minutes with cither additional SF/PRFM (for control) or various concentrations

of cycloheximide in SF/PRFM: 0.5 itg/ml, 1 ug/ml, 5 pg/ml, and 10 pg/ml. Three wells were

used for each treatment. After 30 minutes, 50 ul of 3H-leucine, 1 mCi/ml, were added to each well
and incubation continued for 4 hours. Tritiated waste was removed to radioactive waste

containers. One milliliter of cold phosphate buffered saline (PBS) was added to each well,
incubated for 2 minutes, then removed to radioactive waste. The plates were placed on ice, and a

series of cold 10% TCA washes were performed for 20 minutes. The plates were then washed
with room temperature methanol for 5 minutes. The plates were air dried. One-half oi a milliliter

of 0.3N NaOH in 1 % SDS was added to each well and the plates rocked gently to ensure that the

entire bottom surface was covered with solution. The plates sat at room temperature lor 30
minutes. Contents of the wells were collected, added to 5 ml scintillation fluid, and counted.

Values were averaged for each treatment group.
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R5020 and Cycloheximide Effect:

T47D cells (4.8 X 107) were resuspended in 25 ml of regular BME growth medium and
split into 25 T-150 culture flasks, giving each flask a starting confluency of 13-15%. Cells were

grown to 20-25% confluency with at least one change of medium. On the day of the experiment
the medium was replaced with medium lacking serum, insulin, or phenol red (SF/IF/PRFM) for 4
hours. Duplicate sets of paired flasks were treated with either vehicle (0.1% EtOH), 15 tig/ml

cycloheximide -1- 0.1% EtOH, 10-8M R5020 in 0.1% EtOH, or cycloheximide plus R5020 for 1
hour in SF/IF/PRFM. The final ethanol concentration in each flask was 0.1%. After treatment,

flasks were kept upright at 4°C until harvested to minimize prolonged reaction to the reagents.

Determination of c-myc mRNA Half-life with Actinomycin D:
T47D cells (1.5 x 108) were split into 48 T-150 culture flasks in 10% CS2-FBS medium

and grown to 20-30% confluency with one change of medium. On the day of the experiment, the

medium was changed to SF/IF/PRFM in which the cells were incubated for 4 hours. Cells were
then treated for 1 hour with either 1O8M R5020 in 0.1% EtOH or with 0.1% EtOH alone. At the

end of lhe hour, control and R5020 Rasks in duplicate pairs were treated with lug/ml actinomycin

D for time periods of 0 minutes, 15, 30, 45, 60, or 90 minutes.
After the mRNA for each sample had been isolated and quantitated densitometrically, a

graph of the log of [Initial c-myc mRNA levels]/[c-myc mRNA levels] versus actinomycin D

treatment lime yields a plot from which the slope of the line can be determined. That slope is equal
to k, the first order rale constant for degradation of c-myc mRNA. The halt-life, ti-2, can be
calculated from the equation 11 2 = 0.693/k.

Nuclear Run On Assay:
I. Preparation of Membrane Filter:

cDNA samples, 12 tig each of plasmids pBR322, pRyc 7.4, and pRGPDH, were
linearized with Pst I restriction endonuclease digestion in Promega's IX Buffer H for 1 hour at
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37°C per manufacturer's protocol. Plasmid samples were then heated 5 minutes at 95°C, quick
chilled on ice, and mixed with 1 volume of chilled 20X SSC. Five microgram aliquots of the

plasmids were fixed onto the membrane in parallel lines.

II. Treatment of Cells:
Thirty T-150 culture flasks of T47D cells were grown to 20-30% confluency in 10% FBS
growth medium. On the day of the experiment, medium was replaced with serum-free,

insulin-free, phenol red-free medium (SF/IF/PRFM) for 4 hours, followed by treatment for 1 hour

with cither 10-8M R5020 in 0.1% EtOH or 0.1% EtOH alone. Cells were harvested, centrifuged
al 500 x g for 10 minutes al room temperature, and the pellets frozen at -85°C.
III. Preparation of Nuclei:

Cells w ere retrieved from the freezer and placed on ice to thaw. The ceil pellet was
loosened by gently vorlexing for 5 seconds. NP-40 lysis buffer A (4 ml) was added to the pellet
while gently vorlexing. After the lysis buffer was added, the cells were vortexed an additional 10
seconds at half maximal speed and then placed on ice. One drop of lysed cells was resuspended in

200 id of 1:1 PBS /Harris hematoxylin stain and examined on a hemocytometer to ensure cells
were lysed and nuclei free of cytoplasmic material. To determine the total number of nuclei

retrieved in control- and R5020-trealments, three 10 id aliquots were taken, diluted 10-fold, and

counted on a hemocytometer. The nuclei were centrifuged for 5 minutes at 500 x g at 40C and the
supernatant discarded. The pellet was resuspended in 4 ml NP-40 lysis buffer A as above,

centrifuged again at 500 x g, and the pellet of nuclei resuspended in 200 id of glycerol storage
buffer (see below) with gentle vorlexing. Resuspension was difficult to accomplish, requiring
several short bursts of vortexing. Nuclei were kept chilled on ice between vorlexing episodes.

The original protocol called for freezing the nuclei al - 135°C at this point, to be stored until the
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next step, and also intended that nuclei be counted here. I deviated from this protocol because I did

not feel I could pre-treat, treat, harvest, lyse, count, and isolate nuclei successfully in one day.

IV. Nuclear Run-on Transcription:
Samples, 200 ul each of Control- and R5020-treated nuclei, were transferred to separate

plastic 15ml disposable centrifuge tubes. 2X Reaction Buffer (200 ul) with nucleotides plus 10 ul
of 10 mCi/ml [oc^zp] (JTP were added to the nuclei and incubated for 30 minutes at300C with
shaking in the Gyrorotor water bath.
V. RNA Isolation and Quantitation:
The nuclei were recovered and RNA isolated as described above except that radioactive

wastes were monitored and disposed of according to NRC guidelines. Each RNA sample was
dissolved in 1 ml TES solution in 15ml tubes and shaken for 30 minutes at 30°C in the Gyrorotor
water bath to ensure RNA was completely dissolved. A 5 ul aliquot of each sample was spotted

onto Whatman GF/F glass fiber filters in duplicate and radioactivity counted in 5 ml scintillation

fluid. The samples were diluted as appropriate in TES buffer so that Control- and R5020-treated

samples had equal radioactivity. Ideally, samples were to be 5 X 106 cpm/ml, but samples used
here had 10-fold less radioactive than desired.

VI. Hybridization of RNA to DNA on filters:
The strips of nylon membrane on which the DNA had been applied were coiled and placed

in two separate 5 ml plastic scintillation vials, labeled "Control" or "R5020", and pre-hybridization
solution added to cover the strips. The mixture was warmed to 65°C, 20 ug/ml denatured
sonicated non-homologous Salmon Sperm DNA was added, and incubation continued for 4 hours

in the Gyrorotor water bath with shaking. Radiolabeled RNA (1 ml), control and R5020, was
added to the appropriate vials and incubation continued for 36 hours.

After incubation, the nylon strips were washed twice at room temperature for 10 minutes

in 2X SSPE, 0.1% SDS, once at 65«C in IX SSPE, 0.1% SDS, and again at 650C for 10
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minutes in 0. IX SSPE, 0.1% SDS. The membrane strips were placed in seal-a-mcal plastic and

subjected to autoradiography at -85°C. Upon development of the autoradiogram, no signal was
delected for control samples even though equal amounts of labeled mRiNA had been added to each

nylon membrane strip.

Possible explanations for the difference between intensity of control versus R5020 signals
are (1) cDNAs were not equally affixed to the two nylon strips, (2) less nuclei were obtained for

the control treatment, and (3) dramatically fewer c-myc transcripts were ini tiated/el on gated in
control cells and thus were below detection limits. Signal from the R5020 sample itself was so

faint that the film had to be left for several weeks at -70°C to develop.
The most important change to make to improve the experiment will be to isolate the nuclei
immediately upon harvesting the cells. Another place for improvement could be in the fixation of
cDNA to the nylon membrane. Rather than removing the nylon from the dot blot apparatus prior to

denaturation, one could add the denaturing solution to the sample wells for the prescribed 5

minutes, remove it by vacuum, apply the neutralization solution for 1 minute, remove that solution,
and then dismantle the apparatus. The manufacturer of Hybond-N agreed that this would be an
appropriate method.
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RESULTS

Figure 1 shows the maximum response of R5020 in stimulating production of c-myc
mRNA in T47D breast cancer cells occurs at 10 nM. This is within the physiological range of

serum concentration for progesterone, reportedly 6-64 nM during the luteal phase of menstruation
(Wilson, 1992).
In Figure 2 the time course for c-myc activation by progestins demonstrates that induction

of myc transcription is rapid, reaching maximal mRNA levels at 1 hour. An increase in mRNA
levels has been observed in our lab as early as 5 minutes, although such was not the case for the

experiment illustrated in Figure 2. Nearly a 2-fold increase, however, was observed at 15 minutes
with stimulation continuing to climb, peaking at approximately 4-fold in 1 hour. More typically,
maximal stimulation ranged from 2- to 3-fold, but in all cases occurred with 1 hour of R5020

treatment.
As shown in Figure 3, RU486 reduces c-myc mRNA levels to control values when

administered in conjunction with R5020. RU486 itself, at the concentration used, does not affect cmyc. mRNA expression either positively or negatively. R5020, on the other hand, stimulates cmyc roughly 2-fold. This level of stimulation was statistically different from that observed with all

other treatments, using the Sludent-Newman-Kuels analysis of variance lest (p = 0.0021). No
other treatments were significantly different from one another.
The consensus steroid response element recognized by the progesterone receptor
[GGTACA-NNN-TGTTCT] is also recognized by receptors for glucocorticoids,
mineralocorticoids, and androgens (Clark, 1992). To test if these other steroids would utilize <

mye's putative response element and also affect transcription of the gene, we treated ceils with

representatives from these other classes of steroids. As seen in Figure 4, dexamethasone, a
synthetic glucocorticoid, aldosterone, a mineralocorticoid, and testosterone, an androgen, in
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comparison only weakly enhanced c-myc levels. As had been demonstrated in other cell lines,
estrogen greatly stimulated c-myc, being the most potent mitogen tested here. Treatment with

progesterone elicited a strong stimulation of nearly the same magnitude as R5020. This pattern of
stimulation (Estr. > R5020

Prog.

Dex =Test.= Aid.) was repeated in two additional

experiments, verifying hormone-specific stimulation of c-myc. Whereas stimulation by estrogen

and the progestins was statistically significant, transcriptional enhancement by the other steroids

was not consistently demonstrated.
Al this point all evidence is supporting our hypothesis that enhanced expression of c-myc is

part of the mechanism by which progestins promote growth of T47D breast cancer cells, and that
this effect is a primary one, at the level of transcription. To explore the alternative explanation that

progestins were upregulating c-myc secondary to production of other proteins, cycloheximide
experiments were conducted. This particular inhibitor of protein synthesis operates by "freezing”

ribosomes on polysomes, thus effectively blocking initiation and elongation (Vasquez, 1979).

Unfortunately, cycloheximide itself has been reported by other researchers to cause increases in cmyc mRNA via de-repression (Kelly, 1983; van der Burg, 1989). When protein synthesis ceases,
the production of any labile repressors of c-myc also is stopped. Observed increases in c-myc

mRNA by cycloheximide may be due to de-repression of its synthesis. Being a synthetic reagent,
cycloheximide may also be affecting other cellular pocesses in addition to its action on ribosomes.

Ils total impact on the cell has not been determined.
T47D cell viability was maintained in medium containing as much as 1 mM cycloheximide
(data not shown). In Figure 5 it was demonstrated that protein synthesis was inhibited 90% or

more by cycloheximide doses of 10 and 20 ttg/ml in cells that had been grown for 2 or 5 days in
10% double charcoal-stripped fetal bovine serum (CS-FBS) medium. No significant difference in

the degree of inhibition was observed between 1 and 4 hours of cycloheximide exposure.
Unfortunately, the impact of these conditions on superinduction of c-myc by cycloheximide was
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not tested.
Researchers routinely use cycloheximide as the inhibitor of choice but do so over a range of

concentrations and exposure times. Being aware of the importance that cellular environment may

have on cycloheximde's subcelluar interactions, scientists have also experimented with different
pretreatment protocols. To establish which concentration, duration, and pretreatment would best

suit protein sythesis inhibition in ourT47D cells, I varied each of the parameters and evaluated
their impact on protein sythesis as measured by relative incorporation of tritiated leucine (3H-Leu)

into newly synthesized protein. The results of these three experiments are graphed in Figure 5.
No significant differences in percent inhibition were noted for treatments of 10 versus 20
ug/ml of cycloheximide. The impact of pre-incubating cells in CS2FBS medium for 2 versus 5

days was not significant. The reduced 3H-Leu incorporation noted in cells that had been treated for

5 days in CS-FBS medium and then exposed to medium or cycloheximide and 3H-Leu for 1 hour

was likely due to a limitation in lime allowed for the incorporation of 3H-Leu, 1 vs. 4 hours.
When comparing 3H-Leu incorporation for treatments with equal exposure to the labeled amino

acid, control cells with 2 days of CS2FBS pretreatmenl had 33% less incorporation of 3H-Leu than
cells prelreated for 5 days in CS2FBS medium. This may have been because there were more cells

in the 5-day treatment. I had not adequately controlled for this. In any case, 10-20 ug/ml

cycloheximide reduced protein synthesis 90% or more for every case. In terms of percent
reduction in translation, there was also no significant advantage of prolonged exposure to

cycloheximide over an hour.
Since all the experiments conducted thus far had had a 5-day exposure to CS2FBS medium
prior to initiation of experimentation and I was unable to determine the effect oi cell number on

these results, I continued to use the 5-day pretreatmenl regimen, although it might prove

worthwhile to investigate this more thoroughly . A cycloheximide dose midway between
concentrations tested, 15 ug/ml, was chosen for use in subsequent experiments because this was
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closer to the dosage utilized by Mauvis-Jarvis when demonstrating that estrogen's stimulation of c-

myc was not dependent on synthesis of new proteins (Lcygue, 1995).

In an effort to reduce further basal transcription in the cells, medium was replaced with that
lacking known c-myc stimulants scrum, insulin, and estrogen (in the form of phenol red) for 4

hours before and during the one hour of treatment. Cells were treated with (1) cycloheximide, (2)
R5020, (3) cycloheximide + R5020, or (4) vehicle. Results of this experiment are found in Figure

6. As was reported in other systems, cycloheximide stimulated an increase in c-myc mRNA
levels. This stimulation was slightly less than that of R5020's. Concommitant treatment with

cycloheximide and R5020 showed an additive increase in mRNA, but this increase was not

statistically different from the effect of cycloheximide alone as determined by the Student-NewmanKuels multiple comparison procedure, the p-value being 0.062. Cycloheximide did not interfere
with R5020-slimulation of c-myc, but considering the inhibitor's own contribution to enhancing

mRNA levels, one cannot definitely conclude that progestins stimulate in the absence of ongoing

protein synthesis.

Although dual cycloheximide-R5020 treatments routinely.- showed stimulation over that of
either agent's alone, the addition was always only marginally more than cycloheximde's

stimulation. Figure 7 illustrates the mean of 3 independent experiments of duplicate treatments.
R5020, CHX (cycloheximide), and CHX + R (plus R5020) all are significantly different from
controls but not from one another.
The fact that cycloheximde stimulated c-myc mRNA production to the maximum that we

had observed with R5020 may indicate that this is the ultimate level that c-myc can be stimulated
under our experimental conditions. Even though this experiment could not aid in supporting our
hypothesis, these data at least did not suggest its negation. Perhaps different results would have

been obtained if another inhibitor with a more defined mode of action were used, such as ricin
which inhibits elongation by specific N-glycosidase action on native 28S rRNA (Adams, 1992). If
mRNA lex els rise only as a consequence of mye's de-repression, however, changing inhibitors
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would not help. Considering that c-myc mRNA increases rapidly upon hormonal stimulation
(Figure 2), it is highly unlikely that a new protein is synthesized and elicits its own response in the

time frame observed. Overall, our data suggest that progestin stimulation of c-myc mRNA levels

probably does not require new protein synthesis.
In order to determine whether the increase in c-myc mRNA is due in part to progestin
stabilization of the message, experiments with the RNA synthesis inhibitor actinomycin D were

done. The parallel lines presented in Figure 8 inform us that R5020 does not affect the rate of cmyc mRNA degradation. The slopes of these lines, -0.0296, were calculated by the method of
least squares. The rate constant of the first-order reaction (k) whereby mRNA is being degraded is

equal to this slope. Using the formula ti 2 = 0.693(k)-1, the half-life for c-myc in T47D cells in
our conditions is about 23 minutes. This agrees with half-life determinations for c-myc from other

investigators (Dubik, 1988; Leygue, 1995; Dean, 1986).
Although enhancing the half-life of c-myc message would not preclude R5020's
transcriptional involvement in promoting increases in c-myc mRNA, it would complicate the

determination of progestin's role in c-myc stimulation. As it turned out, R5020 does not alter
mRNA stability and thus, is more likely operating as originally hypothesized, i.e. by increasing the

rate of transcription, a primary effect.
The experiment that will answer this question directly is the nuclear run-on assay which has

so far been inconelusive. The data described above, however, predict that nuclear run-on assays
will show that progestins stimulate the rale of c-myc transcription.
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FIGURE 1:

Dose-dependent Stimulation of c-myc mRNA Levels

Cells were plated at about 15% conflency in plasticT-150 flasks in phenol red-free medium

containing 10% double charcoal-stripped fetal bovine scrum (CS-FBS). They were maintained 5
days in CS-FBS medium with one change of medium. On the day of the experiment, cells

between 20 and 30% con fluency were pretreated 4 hours with serum-free, insulin-free, phenol redfree medium (SF/IF/PRFM). Cells were then exposed, in SF/IF/PRFM, for 1 hour to vehicle

(0.1% ethanol) or R5020 in 0.1% ethanol at concentrations of 10-12 M to 10-6 M. Each treatment

was performed in duplicate.
RNA was isolated from treated cells, and in this experiment, applied to a nylon membrane

using a dot blot apparatus. Nylon blots were probed sequentially with 32p_iabeled glyceraldehyde
phosphate dehydrogenase (GPDH) and c-myc probes. Autoradiograms were analyzed
densilomctrically. Levels of c-myc were normalized against GPDH levels and expressed relative to

control. This experiment was repeated twice, once as above and once using northern blot analysis.

The results were essentially the same.
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FIGURE 2:

Time-dependent Stimulation of c-myc mRNA Levels

T47D cells were seeded al 13-15% confluency in T-75 plastic flasks in medium containing

10% double charcoal-stripped fetal bovine scrum (CS2FBS) and grown for 5 days with one

change of medium. On the day of treatment, cells between 20-30% confluency were supplied with
fresh CS-FBS medium in which vehicle (0.1% ethanol) [C] or 10-8 M R5020 [R] was included.
Cells were treated for 5, 15, 30, 60, 120, and 360 minutes. For treatment times of 1 hour or less,
flasks were chilled in the interim between cessation of treatment and initiation of harvesting to

preclude further cellular processes. Each treatment was done in duplicate.
RNA was isolated from cells and eleclrophoresed on a denaturing 1% agarose gel.

Northern blots were probed sequentially with 32P-labeled c-myc and glyceraldehyde phosphate

dehydrogenase (GPDH) cDNAs. Autoradiograms were analyzed densitomctrically. Levels of c-

myc were normalized with GPDH levels and expressed relative to control.
The representative of three experiments is shown. The amplitude of stimulation varied, but

the pattern of time-dependent stimulation was identical among experiments. The plateau noted
between 15 and 30 minutes of R5020 treatment in Figure 2 was unique to this experiment. In

other experiments, mRNA levels increased from 15 to 30 minutes. In all experiments, the mRNA
levels at 1 and 2 hours of R5020 treatment were statistically different from control.
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FIGURE 3:

The Effect of RU486 ON R5020 Stimulation of c-myc mRNA Levels

Cells were plated in T-175 plastic flasks in phenol red-free medium containing 10%
charcoal-stripped fetal bovine serum (CSFBS) and grown 5 days with one change of medium.
Fresh medium was supplied on the day of treatment. Cells between 20 and 30% confluency were
treated for 2 hours either with ethanol vehicle alone [Ctrl], 10-9 M R5020 [R5020], 10-10 M

RU486 [RU486], or both [R + RU|. All sets contained 0.11% ethanol. Treatments were done

in triplicate.
Because RU486 has been reported to behave as an agonist at higher concentrations, a 100
pM dose was used here. The concentration of R5020, optimal at 10 nM in stimulating c-myc
mRNA levels, was reduced to 1 nM in order that the concentrations of R5020 and RU486
remained comparable. Because this experiment was conducted prior to the time-dependency

experiments, cells were treated for 2 hours, less than the optimal treatment time. As noted in

Figure 2, significant stimulation of c-myc mRNA by R5020, however, is evident still at 2 hours.
RNA was isolated and quantitated as in Figure 2. Data represent the mean of 4 separate

experiments and were statistically evaluated using the Student-Newman-Kuels Multiple
Comparison analysis. Error bars indicate Standard Error of the Mean [S.E.M.). *: R5020

treatment was statistically different (p=0.002) from all other treatments. <p: No other treatments

were significantly different from one another.
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FIGURE 4:

Hormone Specificity:

Stimulation of c-myc mRNA

Cells were grown for 5 days in CS-FBS medium with one change of medium. 4 hours
prior to the experiment the medium was replaced with serum-free, insulin-free, phenol red-free

medium (SF/IF/PRFM). Cells between 20 and 30% confluent were treated in SF/IF/PRFM for 1
hour with vehicle (0.1% ethanol) [C] or the following hormones at a 10-8 M concentration in
0.1% ethanol.

A - Aldosterone
C - Control

D - Dexamethasone
E - Estrogen
P - Progesterone

R - R5020
T - Testosterone

Treatments were done in duplicate and the experiment repeated 3 limes. RNA was isolated and
analyzed as in Figure 2. A representative northern blot and corresponding quantitation ol
dcnsitomelric scans are shown here.
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FIGURE 5:

Cycloheximide Inhibition of Protein Synthesis

In plastic 6-well plates approximately 2 X 105 cel Is/well were seeded , giving a starting
confluency of 10%. Treatments were done in duplicate. Three different treatment regimens were

used.

I. Solid bars
Cells were pretreated for 2 days in medium containing 10% double charcoal-stripped fetal bovine
serum (CS2FBS). Cells between 20 and 30% confluency were treated for 1 hour either with fresh

CS2FBS [CTRL | or cycloheximide [CHX] dissolved in CS2FBS at 10 ug/ml or 20 ug/ml

concentrations. 3H-leucine [Leu| (50 uCi), specific activity of 33 Ci/mmol, was added to each
well. Incubation continued 4 hours.
II. Hatched-crossed bars
Cells were pretreated 5 days in CS2FBS medium with one change of medium. On the day of

treatment, cells al approximately 45% confluency were treated with fresh CS2FBS medium
[CTRL] or with 10 or 20 ug/ml cycloheximide [CHX] in fresh CS2FBS, simultaneously with

50 uCi 2H-leucine per well, for 1 hour.

III. Diagonally striped bars
Cells were pretreated in CS2FBS medium for 5 days as above. Cells were then treated
simultaneously with 50 uCi 3H-leucine and cycloheximide [CHX] or vehicle [CTRL] tor 4

hours.
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FIGURE 6:

Effect of Cycloheximide and R5020 on c-myc mRNA

Cells were grown for 5 days in regular basal medium Eagle (BME) growth medium with
one change of medium. On the day of the experiment, medium was replaced with serum-free,
insulin-free, phenol red-free medium for 4 hours . Cells between 20 and 30% confluency were

then exposed for 1 hour to one of four treatments:
CTRL
R5020

CHX

- 0.1% ethanol
- 10-8 M R5020 in 0.1% ethanol

15ug/ml cycloheximide + 0.1% ethanol

CHX
- 10-8 M R5020 + 15 ug/ml cycloheximide in 0.1% ethanol final concentration
+ R5020

Treatments were performed in triplicate. RNA was isolated, analyzed, and quantitated as in Figure
2. Data are from one experiment. The magnitude of stimulation by R5020 and cycloheximide
varied among experiments, but in all cases was statistically different from controls (p < 0.05). In

each experiment, the cycloheximide + R5020 treatment caused a greater increase in the levels of cmyc mRNA than did treatment with R5020 alone.
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FIGURE 7:

CHX/R5020:

Mean Stimulation of c-my_c mRNA

Treatments were as described in Figure 6. This represents the mean of three such experiments.
R5020, cycloheximide, and cycloheximide + R5020 treatments were all significantly different from

controls, but were not statistically different from one another, using the Student-Newman-Kucls
multiple comparison analysis (p < 0.05).
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FIGURE 8:

Effect of Actinomycin D on c-myc mRNA

Cells were grown for 5 days in medium containing 10% double charcoal-stripped fetal bovine
serum (CS^FBS). On the day of the experiment the medium was replaced with serum-free, insulin-

free, phenol red-free medium (SF/IF/PRFM) for 4 hours. Cells (20-30% confluent) were treated
in SF/IF/PRFM for 1 hour with either 0.1% ethanol [CTRL] or 10-8 M R5020 in 0.1% ethanol
[R5020]. 1 ug/ml actinomycin D was then added to both control and R5020-treated flasks and

incubation proceeded for 0-90 minutes. Northern blots of RNA from these treatments were

analyzed densitometrically. c-myc values were normalized with GPDH values as in previous
figures and expressed as a percentage of initial c-myc mRNA levels for each treatment. The

experiment was repeated 3 times. The apparent increase in % initial c-myc mRNA levels for
control cells over that of R5020-treated cells was not reproducible.
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DISCUSSION

In these studies I have investigated a possible mechanism by which progestins stimulate
growth in T47D human breast cancer cells, namely through transcriptional up-regulation of the

prolooncogene c-myc. I have characterized the increase in c-myc mRNA in response to the
synthetic progestin R5020 in terms of dose-response, the time dependency for stimulation, and

inhibition of R5020 stimulation with the antiprogestin RU486. The hormone specificity for c-myc
induction was also tested with steroids from each of the major classes of classical steroid

hormones. The protein synthesis inhibitor cycloheximide was used to determine if de novo protein

synthesis was necessary for induction of c-myc mRNA. Actinomycin D, an inhibitor of
transcriptional elongation, was used to determine if progestins affected the stability of c-myc
mRNA and to determine the half-life of the c-myc message in T47D cells in our culture conditions.

Expression of c-myc is critical for growth. In the earliest stages of life, c-myc is expressed
at high levels, c-myc mRNA has been detected as early as embryonic day 2 in preimplantation

mammalian embryos, c-myc expression in initiated during the activation of the zygotice genome
after the first cleavage, increases to constitutive levels after the third cleavage (8-cell), and remains
high during differentiation of the 8-cell morulae into blastocysts. Interruption of c-myc expression

halts development al the 8-cell/morulae stage (Paria, 1992). Whereas family members L- and N
rnye's expression is restricted to specific tissue and stages of development, c-myc is more

generalized, found in most proliferating cells (Musgrauer, 1988).
The direct involvement of c-myc in cell cycle progression was suggested by the observation

that transfection of the c-myc gene or microinjection of the Myc protein into quiescent cells enabled

them to enter the cell cycle and replicate (Kaczmarek, 1985; Kingston, 1984). Down-regulation ol
c-myc in P1798 lymphosarcoma cells resulted in a subsequent 50% decrease in the percentage ol

cells in S-phase with a corresponding increase in cells in G^/Gj-phase (Forsthoefel, 1987).

Treatment of T-lymphocytes with antisense c-myc oligonucleotides prevented entry into the
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replicative S-phase of mitosis (Heikkila, 1987). Progression of cells past the restriction point in
late Gi commits cells to DNA synthesis/replication. This progression is dependent on c-myc
expression, but c-myc alone is not sufficient for passage into S-phase. Gj cyclin dependent

kinases, D-type cyclins, the presence of mitogens, and, for many nontransformed cells, an intact

cytoskeleton involved in cell adhesion are also required (Bohmer, 1996; Nass, 1997).
Although high levels of c-myc expression have been noted in rapidly proliferating fetal
epithelial and mesenchymal cells (Schmid, 1989), in tumor cells (Holt, 1988; Marcu, 1992), and in

cells stimulated by growth factors (Reuse, 1990; Haugel, 1992), F9 murine teratocarcinoma stem

cells were reportedly unaffected by enhanced c-myc expression (Schulz, 1989). Down-regulation

of c-myc in F9 cells, however, did lead to growth arrest (Dean, 1986a) and induced differentiation
(Dony, 1985). Cell-cycle arrest due to reduction in c-myc expression has also been reported in the

HL60 promyelocytic cell line (Bentley, 1986). Inhibition of Myc protein synthesis induced HL60
cells to differentiate into mature myeloid cells (Holt, 1988). Inhibition of proliferation in

papovavirus-lransformed C129 murine fibroblasts was preceded by reduction in c-myc mRNA
levels (O'Banion, 1992). Decreased c-myc expression was accompanied by induction of

differentiation in murine erythroleukemic cells (Lachman, 1984), whereas constitutive c-myc
expression blocked their differentiation (Coppola, 1986). In medullary thryroid carcinomas a
reduction in c-myc gene transcription has also been linked to induced differentiation (de Bustros,

1985).
The emerging picture is that in many cell lines up-regulation of c-myc favors proliferation,

whereas attenuation of c-myc expression promotes differentiation. Involvement of c-myc in the

enhancement of growth for MCF-7 breast cancer cells under estrogenic stimulation (Dubik, 1988;

Thomas, 1995; van dcr Burg, 1989) raises the possibility that progestins stimulate the growth of
breast cancer cells through a similar induction of this protooncogene. In the progesterone receptor

(PR)-rich breast cancer cell line T47D, the synthetic progestin ORG 2058 stimulated and then

inhibited cell cycling, c-myc was rapidly but transiently induced by this progestin (Musgrove,

69

1991). The experimental conditions employed during this investigation, however, included phenol

red which may have masked a pure progestin response with respect to c-myc induction since
commercial phenol red has been shown to act as an estrogen (Berthois, 1986). In addition, the
control cells grew very well under the conditions of Musgrove et al. (Musgrove, 1991). Under
our growth conditions (Hissom, 1987; Moore, 1997) control cells grow very' slowly or not at all,

and progestins stimulate growth in a sustained manner. In our hands, if the control cells are

growing rapidly, progestins will not further stimulate their growth (data not shown). The biphasic
regulation of breast cancer grow th reportedly was also affected by progestin-induced expression of

growth factors and their receptors (Murphy, 1985; Murphy, 1991; Musgrove, 1991; Papa, 1990),
although entry of cells into S-phase was shown to precede progestin-stimulated increases of these

growth factors (Musgrove, 1991). Unfortunately, phenol red was included in culture media for

these experiments, as it was in those determining the role of cyclin-dependent kinase inhibitors p21
and p27KiPi in the noted biphasic response of T47D cells to progestins (Groshong, 1997). The

effect of progestins on c-myc mRNA expression in the absence of phenol red, under conditions in

which the control cells grew very slowly or not at all (as in ours), had not been determined in
human breast cancer cells expressing adequate levels of PR such as in T47D cells.
Maximal stimulation of c-myc mRNA occurred with a 10 nM concentration of R5020
(Figure 1). In MCF-7 cells, estradiol at the same dose elicited peak production of the Myc protein

within 90 minutes of treatment (Watson, 1991). In the same cell line a 5.3-fold increase in c-myc
mRNA levels in phenol red-free medium occurred w ith a 10-fold lower dose of estradiol (van der
Burg, 1989). A 10-fold higher concentration, 10-7 M, was needed to achieve a 10-fold induction

of c-myc transcription in medium containing phenol red and 10-6 M tamoxifen, an anti-estrogenic
compound (Dubik, 1988). In normal human breast epithelial (HBE) cells, 10 nM estradiol in
phenol red-free medium was the optimal concentration for stimulation of c-myc mRNA (Leygue,

1995). The concentration of progestin demonstrated as the optimal dose in our experiments is in
agreement with concentrations used in in vitro studies by other researchers and is within the
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physiologically relevant range of hormone concentrations in vivo.

During the normal menstrual cycle, levels of progestogens undergo marked fluctuations.

The menstrual cycle is divided into two phases, a follicular, or proliferative, phase and a luteal, or
secretory, phase. The luteal phase begins at approximately day 14 of the menstrual cycle when the
dominant ovarian follicle ovulates. Changes in cellular structure and function of the follicle result
in the formation of the corpus luteum. With increased vascularization and stimulation by the

luteinizing hormone (LH), the corpus luteum maximally sythesizes and secretes progesterone.

Plasma levels typically arc reported at an average of 36 nM for the duration of the luteal phase
although actual secretion of progesterone is episodic, itself correlating with pulsatile secretion of

LH. With the decline of corpus luteal function, approximately 10 days post-ovulation,
progesterone levels begin to decrease (Carr, 1992).

Our experimental doses of R5020 eliciting transcriptional responses in the c-myc gene are
physiologically relevant and likely reflect actual cellular processes occurring monthly in women.

The synthetic progestin is more stable than progesterone and could therefore effect a greater

response in the microenvironment of a cell where its "apparent concentration" could be slightly
higher due to delays or reductions in its metabolism. Even if this is the case and the concentration

of progestin experienced by the cell is 2- or 3-fold higher than the Ifr8 M treatment we used, the
cell is still seeing no greater PR activation than routinely obseved during menstruation.

Peak induction of c-myc mRNA levels occurred with 1 hour of progestin treatment (Figure

2). van der Burg and co-workers also reported maximal c-myc stimulation at 1 hour but with the

hormone estrogen. Other researchers noted a biphasic increase in c-myc transcription upon

estradiol treatment with the first rise of approximately 10-fold al 20 minutes, followed by maximal
stimulation at 1 hour in MCF-7 cells (Dubik, 1988) or in HBE cells an initial increase in mRNA

levels of 1.9 +/- 0.3-fold after 30 minutes and a comparable stimulation (1.7 +/- 0.3-fold) again
after 60 minutes (Lcygue, 1995). c-myc was also maximally stimulated after I hour of treatment

with thyrotropin in canine epithelial thyrocytes in primary culture (Reuse, 1990). The progestin
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ORG 2058 in T47D cells adapted to grow in insulin-containing serum-frcc medium induced a 3.5-

fold increase of c-myc mRNA levels after only 30 minutes with maximal stimulation of 8-fold after
1-2 hours (Musgrove, 1991).
The rapid increase in c-myc mRNA levels that we observed is in agreement with a model of

progestin transact! vaton of the c-myc gene. One would not expect to observe significant elevation

ol c-myc message earlier than 15-30 minutes following initiation of transcription. Due to the fact
that c-myc mRNA is rapidly degraded or processed in the cell with a reported half-life of only 15-

30 minutes (Dean, 1986; Dubik, 1988; Leygue, 1995), accumulation of myc message likely does

not occur, and observed increases in total c-myc mRNA reflect ongoing transactivation of the gene.
By one hour of hormone exposure to a set of 3 million cells, the majority of c-myc genes being
activated has already occurred and the transcripts processed to maturity. After 1 hour, the balance

of sythesis and degradation favors degradation, c-myc mRNA levels decline to basal levels

following stimulation, unless the mitogen mediates a biphasic increase as has been observed in the
case of estrogenic stimulation of c-myc in HBE cells (Leygue, 1995).
The pronounced effect of R5020 on the cells depicted in Figure 2 likely reflects stimulation

of a population of cells which were more quiescent than other populations we've tested. Control
cells would express much lower c-myc levels, resulting in a higher R5020 stimulation of c-myc
mRNA. Even though protocols to reduce or eliminate growth factors and other mitogens are

utilized in all experiments, variation is still observed. Differences in commercially-obtained serum

is a factor (Forsthoefel, 1987; Leygue, 1995). Preliminary experiments demonstrating progestin's
influence on cell growth, not shown here, revealed a varialon in stimulation that was serm lot

dependent.
T47D cells themselves also inherently contain variables. These cells are known to range in

growth and responses due to slight genetic instability (Reddell, 1988). Passage number, or the

amount of time a particular cell population has been grown in culture, often correlates with such
changes. Although I seldom used cells in experiments that had been maintained in cell culture lor
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more than 400 total passages, I still could have unknowingly used populations with varying basal
growth rales. The lime-course experiments were repealed three times over a span of 2-3 years and

in all cases demonstrated maximal stimulation at 1 hour. The maximum achievable stimulation,
however, fluctuated with passage number and/or serum-medium conditions. As c-myc is known

to respond to a considerable number of reagents, reagents which may not alsways be constant in
cells/serum/medium, it is understandable that stimulation ranged from 2- to 4-fold in the course of
these experiments.

As described earlier, progestins can operate via PR- and PRE-independent pathways to
elicit cellular responses as well as through conventional PR-PRE interactions. RU486, a type I
progesterone antagonist, interferes with progestin activation of genes by binding the progesterone
receptor and effecting PR conformational changes that render it less capable of interacting properly

with transcriptional machinery'. Treatment with RU486 should significantly reduce progestin

stimulation if that stimulation proceeds by PR-mediated mechanisms.
The anti-progestin RU486 abrogated R5020-induced stimulation of c-myc mRNA (Figure

3). This is consistent with reports of RU486 inhibition of proliferation in T47D cells (Bardon,
1985; Gill, 1987) and antagonism of transient increases in percentage of cells in the S-phase of the
cell cycle upon progestin treatment (Musgrove, 1991). Because RU486 does not behave as a pure

antagonist at elevated concentrations, RU486 concentrations of 0.1 nM in our experiments and 0.5
1 nM in the work of Musgrove and co-workers were used. A treatment time of 2 hours for this
experiment deviates from the treatment schedule of the other experiments presented here.
Preliminary work by Dr. Moore and co-workers had suggested 2 hours were optimal in eliciting

cellular progestin-induced responses in T47D cells, and the RU486 experiment was conducted
before I had completed the R5020 time course experiments for c-myc induction. A more

pronounced R5020 stimulation of c-myc mRNA levels would have likely occurred had RNA been
collected after only 1 hour of progestin treatment. Although the effect may have been more
dramatic with a 1 hour treatment regimen, the conclusions would have remained the same. RU486
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negation of R5020 stimulation of c-myc mRNA suggests that progestin enhancement of c-myc
occurs via progesterone receptor-mediated pathways.

These experiments provide support for the hypothesis that progestins stimulate c-myc as a
primary response in which the gene is activated by the liganded PR binding a progesterone

response element (PRE). Additional work performed by Jian-Lang Zhou, a post-doctoral fellow

working in Moore's laboratory, also supports this hypothesis. Using chimeric c-myc reporter
gene constructs including a putative PRE [GGAACC-GCC-TGTCCT] identified by Moore in the

5' upstream region of the human c-myc gene and using the c-myc gene's own promoter, Zhou
found that R5020 treatment caused a statistically significant increase in CAT activity (acetylation of
chloramphenicol) in a hormone- and PR-dependent manner. Fold stimulation w'as similiar to levels

I had observed for c-myc mRNA stimulation in T47D cells. Gel mobility shift assays conducted
by Renee Gentry and Moore also demonstrated specific binding of human progesterone receptor
isoforms A and B with this putative PRE. This binding was enhanced with progestin treatment

(Moore, 1997). Together these data strongly suggest that progestin activation of c-myc is via
stimulation of the rate of transcription.

In Figure 4 the hormone specificity of c-myc induction is illustrated. The only two classes
of steroid hormones which significantly stimulated c-myc expression were progestins (R5020 and

progesterone) and estrogen. None of the other steroids tested here significantly altered c-myc
mRNA levels. Dubik and co-workers likewise did not see alterations in c-myc message with

dexamethasone or testosterone even at 0.1 uM concentrations. The progestin,
medroxyprogesterone acetate (MPA), under their conditions, however, also failed to enhance c-

myc expression (Dubik, 1988). This is likely due to the presence of phenol red in their medium,

such that progestin stimulation was counter-balanced by progestin’s anti-estrogenic effects. In

P1798 lymphosarcoma cells, clone C7, the glucocorticoid dexamethasone reversibly inhibited
initiation of c-myc transcription which was statistically significant al 3 hours and maximal at 90%
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inhibition within 6 hours (Forsthocfcl, 1987). In the L929 fibroblast cell line, 0.1 uM
dexamethasone did not inhibit the c-myc gene (Frost, 1994), although numerous other

investigators have reported glucocorticoid inhibition of c-myc in various cell lines (Eastman-Reks,

i

1986; Forsthocfcl, 1987; Ma, 1992; O'Banion, 1992; Yu, 1989). The effect of other steroid or

II

steroid-like hormones on c-myc transduction has been reported as inhibition by retinoic acid

(Dubik, 1992; Schulz, 1989), stimulation by thyrotropin (Reuse, 1990), by 10 nM hydrocortisone
(Leygue, 1995), and by 30 nM ACTH (Liu, 1996).

The protein synthesis inhibitor cycloheximide at concentration of 10-20 ug/ml has been
reported to superinduce c-myc expression (Dubik, 1988; Kelly, 1983; Leygue, 1995; Lindsten,

1988; Reed, 1986; Reuse, 1990), most likely by de-represson of a labile protein. In order to

determine if on-going protein synthesis was required for hormonal stimulation of c-myc
expression, investigators used cycloheximide in cells pre-treated with medium of reduced

mitogenic potential by eliminating serum (Reuse, 1990), by inclusion of micromolar concentrations

of the anti-cstrogcn tamoxifen (Dubik, 1988), or by removal of serum, phenol red, and any other
known mitogens (Leygue, 1995). Only when cells were sufficiently quiescent at onset of

treatment was the hormonal stimulation of c-myc evident in the presence of cycoheximide. MauvisJarvis and co-workers demonstrated that after4 hours of pre-treatment with basal medium, 10 nM

estradiol + 14 ug/ml cycloheximide caused a 2.5-fold increase in c-myc mRNA levels which
surpassed the 2-fold stimulation by csladiol alone and the 1.5-fold stimulation by cycloheximide

(Leygue, 1995). In tamoxifen-treated MCF-7 cells pre-exposed 2 hours to 50 uM (14 ug/ml)
cycloheximide, Dubik and co-workers demonstrated a relative 12-fold increase in c-myc mRNA
levels after 20 minutes of co-exposure to estradiol and cycloheximide. This was 4X higher than

stimulation seen by cycloheximide alone and more than double that seen by estradiol alone (Dubik,
1988).
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A modest increase in c-myc mRNA levels was observed in cells co-treated with 10 nM

R5020 and 15 ug/ml cycloheximide for 1 hour compared to levels elicited by either reagent alone

(Figure 6). Although this result suggested that de novo protein synthesis was not required for

progestin stimulation of c-myc, additional work did not unequivocally support this (Figure 7).
Because the cells were not equally quiescent at the onset of treatment, fold stimulation by progestin

and/or cycloheximide varied among experiments such that statistical significance was not achieved.
In future studies I would test the various pre-treatment serum conditions reported to be
used in the laboratories of Sutherland (Musgrove, 1991), Mauvis-Jarvis (Leygue, 1995), and Shiu
(Dubik, 1988) for reduction of basal c-myc expression. Combinations of these pre-treatments with
maintenance of cells for 5 days in CS-FBS medium would likely arrest cells in the Go-phase of the

cell cycle in which c-myc expression is repressed (Hann, 1985). Subsequent treatment for only 20-

30 minutes as was done in the experiments of Dubik and Leygue above might allow detection of
hormone induction of c-myc before the effects of cycloheximide reached maximal levels.

coincidentally masking the hormonal effect. Progestins typically do not stimulate c-myc as much

as estrogens do, so the level of c-myc expression after only 30 minutes may not always be

suficiently high to gain statistical significance. Further work is necessary to determine if
cycloheximide can be used in our culture conditions to answer definitely whether or not protein
synthesis is required for progestin stimulation of c-myc. The use of different protein synthesis

inhibitors w ith less pleiotropic effects may also warrant investigation, although work by

Forsthoefel et al. with the inhibitor emetine could not provide conclusive evidence either as the
requirement of on-going protein synthesis for stimulation of c-myc expression (Forsthoefel,

1987).
Although data from our cycloheximide experiments did not exclude the possibility of de
novo synthesis of proteins being involved in R5020 stimulation of c-myc, data from our

limecourse (Figure 1) and reporter gene experiments (Moore, 1997) suggest that protein synthesis

76

is not required. In systems where estrogens stimulated c-myc transcription in the presence of
cycloheximide, thus demonstrating an absence of the requirement for on-going protein synthesis,

estrogens elicited maximal response in the same range of hormonal concentration as did R5020 and

in the same lime period (Dubik, 1988; Leygue, 1995). In both estrogen and progestin cases, up

regulation was rapid, being evident at 15 minutes (see Figure 2). The rapidity alone at with mRNA
elevation was demonstrated strongly suggests no new proteins were necessary for hormonal
induction of c-myc.

■

Studies utilizing the inhibitor of transcriptional elongation, actinomycin D, have

demonstrated that estrogens did not increase c-myc mRNA levels via stabilization of the message.
In the work by Shiu and co-workers the half-life of c-myc mRNA in both quiescent and estrogenstimulated MCF-7 cells was determined to be 18 +/- 7 minutes (Dubik, 1988). In HBE cells

estrogen likewise did not alter c-myc mRNA half-life, ejaculated to be 12 +/- 3 minutes in this cell
line (Leygue, 1995). R5020 stimulation of c-myc mRNA also did not involve alteration of myc

half-life in T47D cells (Figure 8). Initial experiments involving actinomycin D yielded
inconclusive results, but showed no consistent difference between prpgestin-treated and control
cells. The determination of a half-life of 23 minutes for control and R5020-stimulated cells is the

result of only one experiment with duplicate samples. The value of 23 minutes is similar to that
reported by other investigators and reflects the short-lived nature of c-myc mRNA. The main point
of these experiments was to determine if progestins affected message stability. The fact that R5020

treatment did not enhance message stability as a means of increasing mRNA levels further supports
the model that progestins induce increases in c-myc mRNA by action at the transcriptional level.
Direct transduction of the c-myc gene by progestins may be part of the mechanism by which

progestins stimulate the growth of human breast cancer cells.
The down-stream effects of c-myc up-regulation have just begun to be elucidated. Much
information from this on the mechanisms of growth in normal and transformed cells will ensue.

That progestins participate in initiating this proliferative cascade is valuable information that may be
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useful in designing better therapies for the control and treatment of breast cancer.

In conclusion, evidence has been presented supporting the notion that progestins activate cmyc expression in T47D breast cancer cells, probably by stimulation of the rate of transcription.

Additional work to elucidate the complete ramifications of progestin-induction of c-myc in T47D
cells will no doubt show that this phenomenon is part of a complex system of controls that balance

life, growth, and death. This balance is al the heart of a non-cancerous existence which every'

individual craves and, hopefully, someday will achieve.
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SOLUTIONS

In all solutions, "water" was deionized distilled water unless otherwise specified.
Manufacturers of reagents and supplies are listed below.
General Solutions

Gel Loading Buffer: 30% Ficoll, 1 mM EDTA pH 8, 0.25% bromophenol blue, 0.25% xylene

cyanole FF. 3 g Ficoll-400, 40 ul 0.25 M EDTA pH 8, 25 mg bromophenol blue, and 25 mg
xylene cyanole FF per 10ml water.
Prehybridization Solution: 5X SSPE, 5X Denhardt's solution, 0.5% SDS, 50% deionized
formamide, warmed to 420C before addition of 0.2 mg/ml denatured salmon sperm DNA

10% Sarcosyl: 10 g sarcosyl (N-Lauroylsarcosine, sodium salt) per 100 ml water.

20% SDS: 20 g sodium dodecyl sulfate (SDS) per 100 ml water.
20X SSC: In 900 ml water, 175.3 g sodium chloride (NaCl) and 88.2 g Na Citrate were

dissolved. The pH was adjusted to 7.0, the volume brought to 1 liter, and the solution autoclaved.
20X SSPE: In 480 ml waler, 105.19 g NaCl, 9.45 g monobasic sodium phosphate (Na^PCL
HoO), 8.44 g dibasic sodium phosphate (Na2HPC>4 7H2O), and 2.92 g EDTA were dissolved.

Twenty pellets of NaOH were added. The pH was adjusted to 7.7 with more solid NaOH or IN
NaOH. The volume was brought to 500 ml wilh waler and autoclaved.

TE Buffer: 10 mM Tris-HCl pH 8, 1 mM EDTA pH 8.0
Low TE: 10 mM Tris, 0.1 mM EDTA pH 8.0

TE-saturated Phenol: TE buffer pH 8.0,3 ml per 10 ml melted phenol, was mixed in a 50ml

disposable centrifuge tube, vorlexed for 5 minutes, then centrifuged at 500 x g for 15 minutes to
separate phases. Vortexing/centrifugation was repeated until a bi layer was seen. The upper
aqueous layer was removed with a Pasteur pipet. Alternately, 0.05 g 8-hydroxyquinoline, 50 ml

liquified phenol, and 50 ml 50 mM Tris base were stirred in a 250ml beaker for 10 minutes at low
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speed. Phases were allowed to separate at room temperature and the aqueous layer discarded into

waste container. 50 ml of 50 mM Tris-HCl pH8 were added, mixed as above, and this wets
repealed once. The final phenol layer was mixed with 25 ml of 50 mM Tris-HCl pH 8.0 and
stored protected from light at 40C (Aushabul, 1995).

TEPC 1:1 TE-saturated phenol/chloroform. Equal volumes of TE-saturated phenol and

chloroform were mixed at room temperature.

TEPCIA: 25:24:1 TE-saturated phenol: chloroform: isoamyl alcohol. For 50 ml, 25 ml of TEphenol, 24 ml of chloroform, and 1 ml of isoamyl alcohol were combined in a 50ml polypropylene
centrifuge lube. Care was taken not to use polystyrene tubes as these would disintegrate in TEPC.

CeJJLCulture
Charcoal-stripped Fetal Bovine Serum (CS-FBS): One 1 iter of dextran-coated charcoal (DCC)

was divided into 250ml Nalgene centrifuge bottles and pelleted by centrifugation at 2000 x g for 10

minutes (4000 rpm in JA-14). Heal-inactivated FBS was incubated with the pellets from 2
volumes of DCC for 30 minutes al 45°C with constant agitation. To achieve this, the FBS-DCC

mixture was divided into several smaller fractions in separate bottles and placed in the
temperature-controlled Gyrotory Water Bath Shaker, Model G76, at an agitation setting of "5".

Throughout incubation the water level in the bath remained above that of the FBS-DCC fractions.
At the end of incubation the separate fractions were pooled and redivided into balanced 250 ml
centrifugation bottles, spun at 2000 x g for 10 minutes to remove the DCC, and the FBS

supernatant was coarse-filtercd using Whatman or Micron Separations, Inc. filters in a Millipore
filter system. For double charcoal-stripping, the filtered charcoal-stripped fetal bovine serum

(CS-FBS) was incubated again with 2 volumes of fresh DCC, prepared as above, and subjected to

the same treatment as above. Following coarse filtration, the charcoal-stripped FBS (CS-FBS or

CS-FBS) was filtered under sterile conditions through 0.2 urn filter (Nalgene) into a clean
autoclaved medium culture bottle and stored at -20°C.
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Dcjdrarkcoated Charcoal (DCC): DCC was prepared by mixing 2.5 g Norit A activated charcoal,

25 mg Dextran, and 10 ml IM Tris-HCl pH 8.0 per final volume of 1 liter of water.
Growth Medium: One bottle of Gibco-BRL Powdered Basal Medium Eagle, Modified,
Autoclavable, with phenol red was mixed with 4.5 liters of water, pH adjusted to 4.1-4.2,

subdivided into ten clean 500ml tissue culture medium bottles, and autoclaved for 20-30 minutes.
After the solution had cooled to room temperature, the following sterile solutions were added: 15
ml of 7.5% NaHCCh, 5 ml of Gibco streptomycin-penicillin (104 U/ml penicillin; 104 pg/ml
streptomycin sulfate in 0.85% saline), 5 ml of lOmM MEM non-essential amino acids, 4 ml of

previously prepared stock L-glutamine/insulin solution, and 50 ml of fetal bovine serum (FBS)
heat-inactivated at 56°C for 30 minutes. pH was adjusted to 7.2-7.4 with sterile IN NaOH or IM

HC1. The final concentration of ingredients was 0.2% NaHCOa 100 ug/ml streptomycin, 100

unils/ml penicillin, 100 nM non-essential amino acids, 2 mM L-glutamine, 6 ng/ml insulin, and
10% FBS.

L-glutamine Stock Solution: L-glulamine (1.83 g) was dissolved in 50 ml 0.01N HC1 and filtersterilized into sterile 15ml disposable centrifuge tubes.

L-glutamine/insulin Stock Solution: L-glutamine (3.66g) was mixed in a Final volume of 75 ml
0.01N HC1. Insulin (0.15mg) was dissolved in 50 ml 0.01N HC1, and 25 ml of this was added to
the glutamine solution. The stock solution was filter-sterilized (Nalgene, 0.2 um Filler), dispensed

into 15ml polystyrene centrifuge tubes, and stored at -2OC.
Splitting Solution: In a final volume of 995 ml of water, the following were dissolved: 8.0 g

NaCl, 1 g Dextrose , 0.4 g KC1, 0.372 g disodium EDTA (Na2EDTA) or 0.292 g EDTA, 0.09 g
dibasic sodium phosphate (Na2HPO4-7H2O), and 0.06 g monobasic potassium phosphate

(KH2PO4). This was divided into two 500ml bottles and autoclaved for 20-30 minutes. Before
use, 2.35 ml sterile 7.5% NaHCO3 was added to each bottle.

93

RNA Isolation

49:1 Chloroform: Iso amyl alcohol: 0.1 ml of isoamyl alcohol per 4.9 ml chloroform.
0J_% DEPC-HoO: In an open 500ml bottle 0.5 ml of diethyl pyrocarbonate (DEPC) was stirred

10 minutes with 495.5 ml water. The solution was autoclaved, then stirred while still hot in the
sterile hood for 30 minutes with the lid removed. The sealed solution was stored at room
temperature.
Guanidinium Thiocynate Stock Solution: 4M guanidinium thiocynate, 25mM sodium citrate, and

0.5% sarcosyl.
Solution D: 7.2 ul (Tmercaptoethanol per ml of guanidinium thiocynate stock solution.

Water-saturated Phenol: Phenol was warmed to 65°C in the Gyrorotory water bath. Warmed
phenol (20-50ml) was added to a Kimax 500ml separatory funnel and an equal volume of water
added to it. Manufacturer recommendations called for onlv one-fourth the volume of water to
phenol, but experience proved that more water was often necessary to saturate the phenol. The

mixture was shaken vigorously, aerated, and then placed in the cold room, protected from light, to

allow the phases to separate. In 4-8 hrs the lower phenol layer was recovered into a 50ml
polypropylene centrifuge tube. An anti-oxidant, 0.1% (w/v) 8-hydroxyquinoline, was added to

the phenol and mixed by inversion. A thin layer of water was applied to the top of the phenol as

further protection against oxidation. The tube was wrapped in aluminum foil and stored at 4°C.
RNA Electrophoresis and Dot Blots

Deionized Formamide: BioRad AG501-X8 resin (0.05 g per ml of formamide) was mixed 1 hr on
a stir plate. The deionized formamide was then filter-sterilized into a 15ml centrifuge tube using

Gelman 0.2um syringe filters attached to 5ml syringes.

Ethidium Bromide Stock Solution, 10 mg/ml: As ethidium bromide is a putative carcinogen,
gloves were worn when weighing out 10 mg of ethidium bromide and dissolving it in 1 ml sterile
water. The microcentrifuge lube was wrapped with tape to protect the solution from light and
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stored at 4()C, marked as hazardous.

Ethidium Bromide Staining Solution, 5 ug/ml: 150 ul of the 10 mg/ml stock ethidium bromide
solution above were added to 300 ml waler in a plastic tuppcrware dish. The lid was marked with

a cautionary statement as to the danger of the contents. The solution was stored in the dark.

IPX MOPS Buffer pH 7: 0.2M MOPS (3-[N-Morpholino]propanesuIfonic acid), 0.5M NaOAc,
and 0.01 M NaoEDTA. For a final volume of 500 ml, 20.93 g of MOPS, 34.02 g NaOAc, and

1.86 g Na2EDTA were dissolved, and the pH was adjusted to 7. The bottle was wrapped in
aluminum foil prior to being autoclaved. The wrapped solution was stored at room temperature,
but discarded if it became yellow in color.

RNA Denaturing Solution (Dot Blot): 500 id deionized formamide, 162 ul 37% formaldehyde,
and 100 id 10X MOPS buffer.

RNA Gel (1 lx 14cm-): One gram of agarose was mixed with 73 ml sterile water and 10 ml sterile

10X MOPS buffer and boiled 2 minutes until the agarose was thoroughly dissolved. The beaker
was then taken to the chemical hood in which the horizontal gel apparatus was assembled. In the
hood, 17 ml of 13.3M formaldehyde were mixed with the 55-65°C agarose/MOPS solution, and
the gel poured into the gel box. The comb was inserted, and all bubbles moved to the periphery'

with a clean pipet tip. The gel was allowed to polymerize at least 30 minutes before covering with

750 ml of IX MOPS buffer.
RNA Gel Samples: RNA (20 ug in 6 id of 0.1% DEPC-H2O) was mixed with 12.5 id deionized

formamide, 2.5 ul 10X MOPS buffer, and 4 id formaldehyde. Samples were heated to 65°C for 5
minutes in the Fisher Scientific Isotemp Dry Bath 145, quick-chilled on ice, and 2 id oi RNA
loading buffer added. Samples were centrifuged briefly to collect in the microcentriluge and

loaded on the 1% agarose, 2.2M formaldehyde, IX MOPS gel.

95

RNA_Northern Hybridization
JLQQX Den hard t's Solution: 2% (w/v) BSA (bovine serum albumin), 2% (w/v) Ficoll-400, and
2% (w/v) PVP (polyvinylpyrrolidone). In 10 ml water, 0.2 g of each were dissolved, filter-

sterilized, and aliquolcd into 6 autoclaved microcentrifuge tubes. This was stored at -200C.

Salmon Sperm DNA: Salmon sperm DNA (50 mg) was hand-shredded and dissolved in 5 ml TE
Buffer pH8.0. TEPCIA (5ml) was added, vortexed 1 minute, and then chilled on ice. The
solution was centrifuged 1 minute in an IEC Clinical centrifuge at full speed and the aqueous layer

transferred to an autoclaved 30ml Corex tube. DNA was precipitated with 0.1 volume of 3M

NaOAc pH 5.2 and 2.2 volumes of 200-proof ethanol, covered with parafilm, and placed at -20°C
for 1 hour or more. The precipitant was centrifuged at 10,000 x g for 10 minutes at 4°C. The
DNA pellet was washed with 1 ml ice-cold 70% ethanol, dried in vacuo in a dessicator, and

resuspended in 5 ml 0. IN NaOH. This was divided into 4 aliquots and stored at 4°C.
cDNA Probes Maintenance and Isolation
Equilibration Buffer (Sephadex columns): lOmM Tris-HCl pH 8.0, 50mM NaCl, 0. ImM EDTA

pH 8.0, 0.1% SDS.

G-50 Sephadex Slurry: G-50 Sephadex (2g) was mixed with 35 ml of equilibration buffer and
stirred for 24 hours.
GET Buffer: 25mM Tris-HCl pH 7.5, lOmM EDTA, 15% sucrose.
Luria-Bcrtani (LB) Agar Plates: In water, 15g/l Bacto-tryptone + 5g/l Yeast Extract + 10g/l NaCl

+ 15g/l of agar were dissolved. The solution was autoclaved for 25 minutes. When the mixture

had cooled to approximately 50°C, 12.5 itg/ml telracycline-HCl were added. Into each agar plate,
32-40 ml of this were poured in the sterile hood with the lights off. Lids were removed until after

the agar had solidified. Plates were stored in the original plastic sleeve at 4°C in the dark. Plates
were identified with "LB/Tet" marked on the lids as well as the date of production.

LB„Medi_um: In waler, 10g/l Bacto-tryptone + 5g/l Yeast Extract + 10g/l NaCl were dissolved,
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titrated to pH 7.5 with 5N NaOH (approximately 14 drops per .5 liters), and autoclaved. Before

use, 12.5 pg/ml tetracycline-HCl was added to the culture.
Lysis_Buffer: 5.6 ml of GET buffer per 0.6ml of 40 mg/ml lysozyme.
Lysozym_e_Slock,^0_mg/mk In 5 ml of sterile water, 0.2g of lysozyme were dissolved.

13% PEG Solution: 13 g of polyethylene glycol (PEG) per 100 ml water.
Sodium Phosphate Solution: 6.85 ml 0.2M NaHoPO-i HoO + 3.15 ml Na2HPO4 7HoO in 20ml

final volume.
RNase Stock, 4 mg/ml: In 10 ml sterile water, 0.04 g of RNase was dissolved, aliquotted into ten

autoclaved 1.5ml microcentrifuge tubes, and stored at -85°C.
Solution II: 0.2M NaOH, 1% SDS.

25 mg/ml Tetracycline-HCl Stock Solution: Tetracycline-HCl was shipped in vials of 20 mg and
stored at -20°C. Sterile water (0.8 ml) was pipetted into the vial, mixed gently to dissolve the
tetracycline, and stored al 40C with the lid parafilmed. To achieve a final concentration of 12.5

tig/ml tetracycline, 5 id of this stock solution were added per ml of LB medium.

10% TCA: 1 ml trichloroacetic acid (TCA) per 10 ml water.
Experiments
IM Cycloheximide: 28.13 mg cycloheximide per ml of EtOH.

Denaturing Solution (nuclear run-on exp.): 1.5 M NaCl, 0.5 M NaOH
1MDTT (dithiothrcitol): 0.1542 g per ml of water.

Glycerol Storage Buffer: 50 mM Tris, 5 mM MgCL, 0.1 mM EDTA, 40% (v/v) glycerol, pH 8.3
Neutralizing Solution (nuclear run-on exp.): 1.5 M NaCl, 0.5 M Tris, 1 mM EDTA, pH 7.2

NP-40 Lysis Buffer A: 10 mM Tris, 10 mM NaCl, and 3 mM MgCh pH 7.4. The solution was
autoclaved and cooled before 0.5% (v/v) NP-40 was added.

2X Reaction Buffer (nuclear run-on exp.): 10 mM Tris, 5 mM MgCE, 0.3 M KC1, pH 8.0,

97

f

autoclaved.
2X Reaction Buffer with Nucleotides: 10 ul each of 100 mM ATP, CTP, GTP, and 5 til IM DTT

in 1 ml 2X reaction buffer.

TES. Solution: 10 mM N4ris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES), 10 mM
EDTA, 0.2% (w/v) SDS, pH 7.4 , autoclaved.
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REAGENT MANUFACTURERS

Acetic acid, glacial

Fisher

Actinomycin D

Sigma

Activated Charcoal, Norit A

Sigma

AG501-X8 20-50 Mesh Resin

Bio-Rad

Agarose

Gibco-BRL

Alanine

Sigma

Aldosterone

Sigma

Ammonium acetate

Fisher

Bacto-Tryptone

DIFCO

Bacto Yeast Extract

DIFCO

Beta-mercaptoethanol

Sigma

Bromophenol blue

Fisher

Buffer H

Promega

DECAprimc II kit

Ambion

DEPC (diethyl pyrocarbonate)

Sigma

Dexamethasone

Sigma

Dextran (clinical grade)

Sigma

Dextrose

Fisher

Dextrose, anhydrous

MCB *

Disodium ethylenediaminetetraacetate

Fisher

DNA, sodium salt from salmon testes

Sigma

DNA Ladder, 1 kb

BRL*

DNA Mass Ladder

Gibco-BRL

EDTA (cthylencdiaminetetraacetate)

J.T. Baker or Fisher

99

p

Estradiol-17(3

Sigma

Ethidium bromide (electrophoresis grade)

Fisher

Fi col 1-400

Pharmacia

Formaldehyde, 37%

Fisher

Formamide

Fisher

Glutamine

Sigma

Glycerol

Fisher

Glycine (aminoacetic acid)

Sigma

Guanidine thiocynate

Fisher

Hydroxycortisone

Sigma

8-Hydroxyqui noline

Fisher

Insulin

Sigma

Isopropanol

Fisher

Magnesium chloride

Fisher

Magnesium sulfate

Fisher

MOPS (3-[N-Morpholino]propanesulfonic acid)

Sigma

N-lauroylsarcosine, sodium salt

Sigma

Nonidet P-40

Sigma

Penicillin-Streptomycin

Gibco-BRL

Phenol

BRL Life Technologies

Phosphoric acid, concentrated

J.T. Baker

Potassium chloride

Fisher

Potassium phosphate dibasic, anhydrous

Fisher

Potassium phosphate monobasic

Fisher

Progesterone

Sigma
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Psi 1 restriction endonuclease

Promega

P VP-40 (polyvinylpyrrolidone)

Sigma

Random Primers DNA labeling system

Gibco-BRL

R5020 (17,21-dimethyl- 19-nor-4,9pregnadiene-3,20-dionc)

Roussel-UCLAF

RNA Ladder, 0.24-9.5 kb, lug/pl

Gibco-BRL

RU486 (17(3-hydroxy-1 ip-(4-dimethyl-aminophenyI-l)17cc-(prop-l-ynil)-estra-4,9-dien-3-one)

Roussel-UCLAF

SDS (sodium dodecyl sulfate)

Bio-Rad or J.T. Baker

Sephadex G-50

Sigma

Sodium acetate

Fisher

Sodium bicarbonate

Fisher

Sodium chloride, U.S.P. granular

Fisher

Sodium citrate

Fisher

Sodium hydroxide

Fisher

Sodium molybdate

Fisher

Sodium phosphate dibasic heplahydrale

Fisher

Sodium phosphate monobasic

Fisher

TES

(N-tris(hydroxymethyl)mcthyl-2-aminoethanesulfonic acid) Fisher
T cstostcronc

Sigma

Tetracycline-HCl

Sigma

Trizma Base (Tris [hydroxymethyl ]aminomethane)

Sigma

Xylene Cyanole FF

Sigma

* MCB - Matheson, Coleman, & Bell
* BRL - Bethesda Research Laboratories
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ABBREVIATIONS & ACRONYMS

A

adenine

ACTH

adrenocorticotropic hormone

AR

androgen receptor

ATP

adenosine tn phosphate

AUG

codon for methionine

BBC1

breast basic conserved-1 gene

bp

base pair

BRCA1

Breast cancer gene-1

BRCA2

Breast cancer gene-2

8-Br-cAMP

8-bromo-cyclic 3', 5'-adenosine monophosphate

BRL

Bethesda Research Laboratories

BUS

B-upstream segment of hPR-B

C

cytosine

cAMP

cyclic 3',5'-adenosine monophosphate

CAT

chloramphenicol acetyltransferase

CBG

corticosteroid-binding globulin

CBP

CREB-binding protein

cc

cubic centimeter

C/EBPcc

CCAAT/enhancer-binding protein a-gene

CHX

cycloheximide

cM

centi Morgan

CS2FBS

double charcoal-stripped fetal bovine serum

DBD

DNA-binding domain
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DEPC

diethyl pyrocarbonate

DHFR

di hydrofolale reductase gene

DMSO

dimcthylsulfoxide

DNA

deoxyribonucleic acid

DPEP1

dipeptidase-1 gene

dsRNA

double-stranded ribonucleic acid

dTTPs

deoxy thymidine triphosphates

EDTA

ethylenediamine tetraacetate

e.g.

exempli gratia (Latin): for example

EGF

epidermal growth factor

ER

estrogen receptor

ERE

estrogen response element

et al.

et alia (Latin): and others

EtOH

ethanol

FBS

fetal bovine serum

FGF

fibroblast growth factor

FGFR

fibroblast growth factor receptor

FMO5

Ravin-containing monoxygenase 5

G

guanine

GR

glucocorticoid receptor

GRIP

glucocorticoid receptor interacting protein

HoO

w a ter

H8

cyclic nucleotide-dependent protein kinase inhibitor

HAT

histone acetyltransferase

HBE

human breast epithelia (cells)

HD1

histone deacetylase-1
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hER

human estrogen receptor

3H-1CU

leucine radioactively labeled with tritium

H-L-H

helix-loop-helix

HMG-1

high mobility group-1 chromatin protein

hPR-x

human progesterone receptor-x where x = A, B, or C isoforms

hr

hour

HRE

hormone response element

hsp

heat shock protein

IGF-1

insulin-like growth factor-1

IL-2

inlcrleukin-2

k

first-order rate constant

k-1

dissociation rate constant

Ka

equilibrium constant for dissociation

kb

kilobase

kDa

kilodaltons

Leu

leucine

LDH

lactate dehydrogenase

LH

luteinizing hormone

LOH

loss of helerogosity

m

symbol for the slope of a line

M

molar

Max

myc Associated X

MCB

Matheson, Coleman, & Bell

MEN-1

multiple endocrine neoplasia type I

min.

minute

ml

milliliter, 10-3 1
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mM

millimolar, IO--3 M

MOPS

3-(N-Morpholino)propancsulfonic acid

MPA

medroxyprogesterone acetate

MR

mineralocorticoid receptor

mRNA

messenger ribonucleic acid

NCoA

nuclear co-acti valor

NLS

nuclear localization signal

nM

nanomolar, IO9 M

NME-1

encodes metastasis inhibitor protein nm23

P

short arm of the chromosome, from the French petit

PAGE

polyacrylamide gel electrophoresis

PBS

phosphate buffered saline

p/CIP

p300/CB P/co-i ntcgrator-associated protcin

PDGF

platelet-derived growth factor

PDI

protein disulfide isomerase

PEG

polyethylene glycol

PHA

ph\ lohemaggl uti ni n

PKC

protein kinase C

PKI

protein kinase A inhibitor

PMSG

pregnant mare serum gonadotropin

PVP

pol \v i ny 1 pyrrol idone

q

long arm of the chromosome

R5020

17,2 l-dimcthyl-19-nor-4,9-pregnadiene-3,20-dione

RA

retinoic acid

RAR

retinoic acid receptor

RBF

receptor binding factor
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can

rpm

revolutions per minute

rRNA

ribosomal ribonucleic acid

RU486

17[3-hydroxy-11 (3-(4-dimethyl-aminophenyl-1)- 17a-(prop-1 -ynil)-estra-4,9-diene-3-one

SCLC

small cell lung cancer

SDS

sodium dodecyl sulfate

Ser

serine

Sf9

Spodoptera frugiperda insect cel 1 s

SF/IF/PRFM serum-free, insulin-free, phenol red-free medium

SR

steroid receptor

SRC

steroid receptor coactivator

SRE

steroid response element

T

thymine

T3B (T3p)

thyroid hormone (3, 5, 3'-lriiodothyronine)

TAF-n

transcription activation (or transactivalion) function-n where n=l,2, or 3

TBP

TATA-binding protein

TCA

trichloroacetic acid

TcBG

testosterone-binding globulin

TES

N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid

TGF

transforming growth factor

TIF-2

transcriptional intermediate factor-2

TNF-a

tumor necrosis factor-a

TPA

12-O-tetradecanoyl phorbol- 13-acetate

TSG

tumor suppressor gene

microgram, 10-6 gram
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pl

microliter, IO6liter

UTP

uridine triphosphate

VDR

vitamin D receptor

vitERE

vitellogenin estrogen response element

YY1

Yin-Yang-1 transcription protein
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ABSTRACT

Moore and co-workers have previously demonstrated that progestins stimulate the growth
of T47D human breast cancer cells. We now investigate the possibility that progestins might

transactivate the protooncogcne c-myc as part of the mechanism for growth stimulation. Treatment

of T47D cells with the synthetic progestin R5020 results in a rapid, dose-dependent increase in cmyc mRNA. This stimulation is evident as early as 5 minutes, increases up to 4-fold at 1 hour,

and then returns toward basal levels. The optimal concentration of R5020 for induction of c-myc

gene expression is 10 nM, which is within the physiologically relevant range of hormone
exposure. Co-treatment of T47D cells with R5020 and the anti-progesterone RU486 results ii
abrogation of R5020-induced increases in c-myc mRNA levels. These results suggest that R502u

is operating through the progesterone receptor in transactivating the c-myc gene. Stimulation of cmyc expression is specific for progestins and estrogen. Treatment with 10 nM androgens,

glucocorticoids, and mineralocorticoids has little or no affect c-myc mRNA levels. An increase in
c-myc mRNA levels upon exposure to progestins occurs even in the presence of the protein

synthesis inhibitor cycloheximide. Treatment with cycloheximide itself, however, also results in
significant elevation of this mRNA. Experiments utilizing actinomycin D demonstrate that R5020
does not alter c-myc message half-life. The half-life of c-myc mRNA in T47D cells grown under

our culture conditions is 23 minutes, which is consistent with values reported by other
investigators. Together the data suggest that progestins stimulate c-myc expression as a primary

response, that is, by direct enhancement of transcription of the c-myc gene via classical steroid

hormone receptor pathways. This conclusion will have to be confirmed by nuclear run-on assays.
Increased expression of the c-myc gene may be part of the mechanism by which progestins

stimulate growth of T47D human breast cancer cells and impact on the progression of cancerous
lesions of the breast.
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